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Summary
Research into miRNA, discovered in 1993, has exploded and revolutionized our understanding
of molecular regulation in biological systems. MicroRNAs are now a well established as a regu-
latory mechanism of many pathways and functions within cells of eukaryotic organisms, though
much needs to be learnt about the intricacies of such regulation. In recent years, targeting this
system of post-translational regulation has been a goal of many therapeutics, but requires much
greater insight into how miRNA work, and the broadness of their activity.
The innate immune system is critical for mounting an effective response against invading pathogens
and protecting the host from damage. But being such a powerful system, unchecked it can
wreak havoc on the host itself. While the innate immune system is tightly regulated by many
mechanisms, further understanding could lead to major advances in therapeutics of autoim-
mune diseases. As the miR-17-92 cluster has already been identified as a regulator of innate
immune functions, and continued research in animal models is necessary for therapeutics to
become a reality.
This thesis focuses on the role and function of the miR-17-92 cluster within macrophages, which
are a major component of the innate immune system. It highlights the complexity and often
subtle nature of microRNA regulation in biological systems. It describes the generation of a
mouse line with a myeloid-specific deletion of the miR-17-92 cluster is described, and shown
that despite this deletion, there is no change both to the innate immune response of these mice,
or to the TLR signalling cascade. It is postulated that while the miR-17-92 cluster affects innate
immune signaling in some other cell types, it is unlikely to have a similar role in macrophages.
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1 Introduction
1.1 miRNA
MicroRNAs (miRNAs) are small ~22 nucleotide RNA molecules that regulate the expression of
genes in a sequence-dependent manner. They bind to complementary sequences, often within
the 3’ UTR of messenger RNA (mRNA) and sequester, deadenylate, inhibit ribosomal trans-
lation, or in cases of exact complementarity, enzymatically cleave a target mRNA [1]. Such
mechanisms destabilise the mRNA molecule, and thus prevent protein translation. Initially dis-
covered as critical regulators of worm growth [2], miRNA quickly become understood as a key
mechanism of gene regulation in cells [3].
miRNAs, like genes, are differentially expressed in tissues and can be further influenced by
stimulation, activation and environmental factors. Their regulatory effect is recognised as a
integral component for the survival of organisms and cells, tuning critical processes including
apoptosis, inflammation, and metabolism [4]. miRNA use a “seed sequence” of 6 nucleotides,
between positions 2-8 of its 5’ terminal end to bind target mRNA, at a site known as the miRNA
Response Element (MRE). As the complementary sequences to these seed sequences are re-
peated both perfectly and imperfectly many thousands of times in the genome, the number of
genes a single mature miRNA binds to quickly multiplies to several hundred [5, 6, 7, 8]. Further-
more, imperfect sequence complementarity, as well as different numbers of MREs found on a
single mRNA allows for a variety of strength in interactions between mature miRNA and differ-
ent target sequences. This observation of has led groups to develop software and algorithms
to predict miRNA interactions with target mRNA 3’UTRs [9, 10].
As some miRNA share seed sequences with other miRNA, they are likely to target the same
genes, and are therefore considered part of the same miRNA family. As such, the dysreg-
ulation of a single miRNA can either have widespread consequences for aberrant epigenetic
regulation, not least considering other transcription factors that are downstream of such mod-
ulation, or redundancy by expression of other miRNA family members can mediate the effects
[6]. However, because of the potential breadth of these effects, the dysregulation of a single, or
groups of miRNA are often associated with diseases, including arthritis [11, 12, 13], cholesterol
metabolism and atherosclerosis [14, 15], and colitis [16] to name a few.
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1.2 Biogenesis and processing of miRNA
The pathway to a mature miRNA begins in the nucleus as a primary transcript (pri-miRNA) is
generated by RNA polymerase II, which folds on itself to form a large hairpin structure. pri-
miRNA can be a part of other genes, found within introns, or expressed independently with
their own genomic regulatory elements and promoters [17]. Stem-loop structures found in the
pri-miRNA, after folding in on itself, are recognised by DGCR8, binding to the junction between
the single-stranded RNA and double-stranded RNA of the pri-miRNA. DGCR8 then recruits
Drosha, which in turn cleaves the molecule ~11bp from this junction [18]. The resulting stem-
loops are called precursor-miRNA (pre-miRNA), and contain mature miRNA sequences in the
stem section. These pre-miRNA are exported to the cytoplasm by Exportin 5 [19] (Fig. 1), where
once in the cytoplasm, another RNAse enzyme, Dicer, cleaves the loop off the pre-miRNA to
form a miRNA duplex with a 3’ overhang. Either strand of the duplex miRNA is now loaded in
the RNA-Induced Silencing Complex (RISC), a structure comprising of an Argonaute protein,
TRBP and Dicer, to form the mature miRNA [20, 21]. miRNA can regulate target mRNA by
either repressing ribosomal activity, cleaving the target, or deadenylation [22, 23]. As mature
miRNA can arise from either complementary strand of pre-miRNA, modern nomenclature states
that the mature miRNA loaded RISC with the 5’end of the stem-loop are termed -5p (ie. mmu-
miR-19b-5p), while those from the 3’end are called -3p (ie. mmu-miR-19b-3p).
The miRNA gene silencing pathway has been found to be useful in biological research, as hi-
jacking the biogenesis pathway results in targeted silencing of genes, commonly known today
as Short Hairpin RNA (shRNA) gene silencing [24]. However, the use of RNA silencing tech-
nologies for therapeutics has been slow to develop, mostly due to difficulties and complications
with the delivery and efficacy of such drugs to target cells without undesirable side-effects [25].
Others have had more success, using polymer nanoparticle based delivery systems to inhibit
miR-155 in vivo [26], while others have used SELEX-based approaches to develop cell-specific
aptamers [27]. More recently, new methods of “zipping” miRNA together have been developed,
however questions still remain regarding in vivo evidence, off-target effects, and nucleic acid
acid-sensing PRR activation [28].
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Figure 1:
Biogenesis and effector mechanisms of miRNA. Pri-miRNA are generated in the nucleus,
where they are cleaved by Drosha and DGCR8 into hairpin structures, that are exported to the
cytoplasm by Exportin-5. Once in the cytoplasm, the loop is trimmed by Dicer, and one of the
strands of the miRNA will become a core component of the RISC. Now, the mature miRNA will
guide the RISC to inhibit, and often destabilise messenger RNA, resulting in its degradation.
Image adapted with permission from M.P. Gantier.
1.3 miR-17-92
The miR-17-92 cluster (Fig. 2 ), also known as oncomiR-1, is a major focus of cancer re-
search [29, 30]. Initially it was discovered as a novel gene, chromosome 13 open reading
from 25 (c13orf25) in human B-cell lymphoma, where the region was significantly upregulated
[31]. Currently identified as Mir17HG, it encodes 6 separate miRNAs from 4 different families,
miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92a. There are also two identified
paralogues of the miR-17-92 cluster, called the miR-106a-363 and miR-106b-25 clusters, ex-
pressed on chromosomes X and 7 respectively [32].
Even though there are 6 mature miRNAs from a single transcript, each individual mature miRNA
is expressed at different levels. In a recent study, the complex secondary and tertiary structure
of the miR-17-92 cluster was published, and indicated that the Drosha cleavage sites were inac-
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cessible for pri-miR-18a, -19a and -20a due to its folding [33]. Furthermore, another part of the
pre-miR-17-92 sequence (termed NPSL2) even binds and sequesters a component required to
form the basal helix structure for pri-miR-92a, preventing Drosha processing at all. This led the
authors to believe that the tertiary structure provides a first layer of regulation for the expression
of each individual pri-miRNA. Furthermore, this indicates that other factors must act to expose
these cleavage sites and allow processing, possibly providing a secondary layer of miRNA
expression control. One potential candidate is KHSRP, previously published to enhance miR-
20 expression, however the precise mechanism is unknown [34]. Previously, hnRNP A1 was
shown to bind pri-miR-18a before Drosha processing, indicating another potential candidate for
multilayer regulation of miR-17-92 mature miRNA expression [35].
The mir-17-92 cluster was found to be upregulated by the transcription factor c-myc, and could
facilitate the inhibition apoptosis, resulting in accelerated tumour growth [36]. Deleting the clus-
ter in mice resulted in the death of animals shortly after birth with developmental defects of the
heart, lungs and skeletal structure, a reduced body mass, and a near complete ablation of pre-B
cells [37]. Later work established that the lung hypoplasia is due to the combined contribution of
miR-17, miR-18 and miR-92 deletion, while miR-17 and miR-18 deletion was responsible for the
ablation of mature B-cells [38]. A role of the miR-17-92 cluster was then established in adaptive
immunity, especially in B-cell survival, B-cell related cancers, including lymphomas [39].
Further studies have published that miR-19 modulates the stability of several negative regu-
lators of NF-κB, thus enhancing pro-inflammatory cytokine production [40], while other groups
have confirmed these discoveries in T cells [41], and have further identified miR-19 as an in-
dicator in TH2 driven asthma by the targeting the same genes [42]. However, miR-19 is not
solely responsible for all immune-related diseases are caused by dysregulation of the cluster,
as miR-92a has also been discovered to have a role in Type I diabetes in T cells [43], and
miR-18a was also described to target PIAS3; the regulator of STAT3 signalling in hepatocytes
[44], and miR-20a targets ASK1, decreasing LPS induced cytokine release in arthritis models
[12]. It is also indicated that miR-18 expression is induced via TNFa, which could play a role in
other cells. To this end, it has also been found that miR-18a is induced by NF-κB in Rheumatoid
arthritis Synovial Fibroblasts, and by increasing the expression of miR-18a, there was also an
increase in Il-8, RANTES and other pro-inflammatory markers [45]. More recently, ILC2s were
also found to harbor important roles for the miR-17-92 cluster, where dampened expression of
the cluster resulted in reduced counts of ILC2 cells in the lungs of mice, defective IL-33 driven
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proliferation and inhibited the IL-13 and IL-5 response to the allergen papain [46]. Overexpress-
ing the cluster had the opposite effect, and most of the effects were attributed to miR-19, which
when expression was recapitulated in vivo reversed much of the miR-17-92 deficient observa-
tions. A critical challenge for researchers trying to study the miR-17-92 cluster is that it affects
such a wide variety of pathways in the cell. Making a complete KO cell is made difficult when
the cluster is critical for cell survival [32], which explains why other studies have had trouble
using and making miR-17-92 KO cells lines [42].
1.4 Innate immune system and inflammation
The innate immune system is the first line of defense against invading pathogens in complex
multicellular organisms. It consists of physical barriers including the skin and secreted fluids,
like saliva and mucus, that non-specifically limit the invasion by pathogens into the body, and
then effector cells and mechanisms, including (but not limited to), macrophages, dendritic cells,
and mast cells. Indeed, most cells in the body, such as fibroblasts, possess some function for
innate immunity, sensing microbial pathogens and activating transcription factors that activate
chemokine release, encouraging the mobilisation of other effector cells to the site of infection.
Pathogen Associated Molecular Patterns (PAMPs) are conserved structures and components
of pathogens, and Danger Associated Molecular patterns (DAMPs) are molecules from the
host organisms, that would not normally be found in the extracellular space, but their presence
may indicate an infection or damage to the host. Both PAMPs and DAMPs can be specifically
recognised by conserved receptors, called Pattern Recognition Receptors (PRRs), which are
found in and on different innate immune cells. Included in this family of receptors are the Toll-
like receptors (TLRs), the NOD-like receptors, RIG-I like receptors and C-type lectin receptors,
all of which are evolutionarily conserved to recognise particular motifs from bacteria, viruses,
parasites and fungi [48, 49].
Inflammation is one of the major responses to invading pathogens, typified by a reddening and
swelling of the affected tissue, often accompanied with tenderness or pain. PRRs from either
local epithelial cells, tissue resident macrophages or dendritic cells identify foreign material from
bacteria, viruses, and other invading pathogens, and release pro-inflammatory signals such as
cytokines. This signal results in a rush of blood and fluids to the affected area, bringing with it
recruited activated effector cells such as neutrophils and monocyte-derived macrophages. This
rush in blood and fluid reddens the area, and increases the swelling of the tissue.
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The detection of PAMPS triggers a signalling cascade from the recruitment of the adaptor
molecules MyD88, with or without TRIF, and switches on signalling networks that induce the
production and secretion of pro-inflammatory cytokines, chemokines, interferons (IFNs) and
other anti-microbial agents, which mount responses to fight infection by pathogens. Typically,
when tissue resident macrophages encounter an invading pathogen, their PRRs are activated,
and they begin to phagocytose, followed by the release of the cytokines TNFα, IL-6, and IL-1β,
and sometimes more, depending on the PRR activated [50].
Macrophages typically clear dead cells, pathogens and debris, while dendritic cells remove
antigens, and migrate to the local lymph nodes to activate and mature T and B cells.
1.5 Macrophages
First described as “Big Eaters” by their discoverer, Elie Metchnikoff, macrophages have become
recognized as critical cells of the innate immune system [51, 52]. There are many subpopula-
tions of macrophages identified, typically distinguished by their location in the body, and are de-
rived from embryonic precursor cells [53, 54]. Tissue resident macrophages include peritoneal
macrophages, microglia in the brain, and kupfer cells in the liver to name a few. Macrophages
have diverse and important functions in the body, patrolling for invading pathogens, initiating
innate immune responses, remodelling and repairing of tissues following an infection or inflam-
mation, and resolving the inflammatory response. In the event of inflammation or other stimuli,
monocytes that are recruited to the site of infection may also differentiate into macrophages,
given the right conditions and presence of macrophage colony stimulating factor (M-CSF). Their
major function is the phagocytosis of invading pathogens and antigens, which can be degraded
by the macrophage itself using lysosomal compartments filled with degradative enzymes. If a
macrophage is activated by the detection of a PAMP or DAMP, a rapid change in metabolism
and gene expression is observed, and the cell may release pro-inflammatory cytokines IL-1,
IL-6 and TNFa. Other release cytokines include IL-8 to recruit and attract neutrophils, and IL-12
to activate NK cells, and initiate the differentiation of TH1 cells. Other macrophages will also try
and resolve the response by secreting IL-10, returning the conditions back to normal [55].
Critical functions of macrophages are known to be regulated by many miRNA. For example,
miR-146a and -146b are both upregulated following stimulation of cell surface receptors [56,
14]. More recently, expression of miR-146a was found to be controlled by PU.1 and ApoE in
mouse macrophages [15]. These miRNA target TRAF6, IRAK1, IRAK2, all components of the
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myddosome, a protein scaffold required for many TLR and TNFR signalling cascades [57]. As a
consequence of miR-146a/b targeting of these regulatory components, expression and release
of many inflammatory cytokines such as IL-8 and RANTES following stimulation are reduced
[57, 58]. Because of these mechanisms, miR-146 has also been associated with diseases and
disease processes such as atherosclerosis, cholesterol efflux and metabolism to name a few
[15, 14].
Other effects are not as direct, such as miR-132, which was found to target acetylcholinesterase
(AChE) in murine macrophages [59]. AChE breaks down acetylcholine, which is released by
the vagus nerve to dampen peripheral inflammatory responses [60, 61]. In macrophages, miR-
132 was reduced upon LPS stimulation allowing for miR-132 regulation to permit acetylcholine
driven inflammatory regulation. By mutating the miR-132 target site in AChE in a mouse model,
the mice exhibited enhanced pro-inflammatory cytokine release when challenged with LPS [59].
miRNA expression may also be regulated by environmental stresses or stimuli. IL-10, a critical
anti-inflammatory cytokine released by macrophages also inhibits the induction of miR-155 by
TLR signalling in macrophages [62]. This is a critical step to reduce and control inflammation
in macrophages [63]. miRNA also have very complicated roles in macrophages and may also
have delicate interplay may be important for context dependent responses. As both miR-146
and miR-155 are induced by NF-κB mechanisms, and where miR-146 is more anti-inflammatory
[64], miR-155 has a wide range of effects on NF-κB, but is not limited to just pro-inflammatory
roles [62, 63, 65]. While miR-146-/-macrophages were found to be pro-inflammatory, the effect
was entirely dependent on the expression of miR-155 [66].
1.6 Regulation of NF-kB and Inflammation
The NF-κB family of transcription factors (consisting of p50, p52, RelA, RelB, and c-Rel) is one
of the major drivers of inflammation, and were initially found in B-cells in 1986 [67]. NF-κB
members are found in the cytoplasm of most cells pre-formed in homo- or heterodimers of 13
different forms, but are sequestered by bound proteins; Inhibitors of κB (IκBα, IκBβ, IκBε, and
more) [49, 68, 69, 70, 71]. The N-terminal subdomain is responsible for DNA recognition and
binding, while the C-terminal domain of these family members is responsible or dimer formation
and inhibition. Furthermore, with such a wide variety of NF-κB dimers possible, it is easy to
see that these subtle differences may allow for different affinities to unique sequences of DNA.
There are two methods of activating NF-κB to translocate to the nucleus, the Classical pathway
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and the Alternative pathway. It is largely accepted that the Classical pathway is associated
with response to infectious agents and inflammatory insults, while the alternative pathway is for
developmental signals [71].
For the Classical pathway, a surface receptor such as a PRR or TNFR undergoes a confor-
mational change allowing for interaction with downstream molecules including MyD88, IRAK-1,
IRAK-4, RIPK1, TRADD, TAK1 and TRAF6, depending on the specific receptor activated. This
activation is often concurrent with the addition of a K63 ubiquitin chain to these adaptor proteins
[72, 73, 74]. These adaptor proteins will trigger a signalling cascade that results in the activation
of Inhibitor of kB Kinases (IKKα, IKKβ and IKKγ), whose function is to phosphorylate the IkBs,
triggering their ubiquitination and degradation, and thus releasing NF-κB dimers to migrate to
the nucleus [75, 76, 49, 77, 71, 78]. Once there, NF-κB binds in a sequence dependent manner
to the DNA sequence 5’-GGGRNWYYCC-3’ (N, any base; R, purine; W, adenine or thymine; Y,
pyrimidine), called kB, which modulates expression of specific genes [71]. Genes associated
with cytokine expression are often upregulated, and the cells shift towards a glycolytic metabolic
setting, as the cell begins to produce lots of cytokines and other proteins associated with com-
bating the invading pathogen [79, 80]. It is quite clear that with several NF-κB family members
and multiple possible dimers, the potential for differential DNA binding and recognition can result
in many transactivation mechanisms [70].
Continual low-grade inflammation can, in time, result in an imbalance of the immune homeosta-
sis, leading to tissue damage, autoimmune and inflammatory diseases such as arthritis, and
cancers [81, 50]. The control of inflammatory signals is also critical for normal development,
as NF-κB has been found important in the development of many tissues [82]. To prevent dys-
regulation of inflammation, there are many negative regulators that are induced following an
inflammatory signal that try to shut down NF-κB and the inflammatory response. These built-in
negative feedback loops allow for a pulsatile response, continually keeping the system under
self-check [83, 84, 85]. Tnfaip3 (A20) is among these genes, which edits the ubiquitination of
TRAF6 and RIPK1. Upon activation and translocation of NF-κB to the nucleus, genes including
Tnfaip3 are induced [86, 87, 88]that then remove the K63 polyubiquitin from TRAF6 and RIPK1,
and replace them with K48-linked polyubiquitin [72]. Importantly, the biogenesis of miRNA is
also modified by activation of inflammatory cascades and transcription factors [89, 84, 90], thus
bringing a new dimension to miRNA regulation of gene expression.
As inflammation is such an important pathway that must be tightly regulated, it makes sense
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that miRNA can modulate such cellular responses. Indeed, miR-146a, miR-155 and miR-132
were found to be induced following LPS stimulation. Furthermore, miR-146a could regulate
IRAK1 and TRAF6, hence providing a negative feedback loop to curb the inflammatory signalling
cascade [56, 91, 92]. Independent analysis shows that miR-155 was indeed induced by LPS
and TNFa, further highlighting their roles as regulators of inflammation and endotoxic shock
[93, 94]. Even more importantly, miRNA are also under the control of negative regulators of
NF-κB and inflammation, as was discovered when IL-10, an anti-inflammatory cytokine could
inhibit the induction of miR-155 following TLR activation [62]. Furthermore, miR-125a and -
125b have been previously shown to regulate A20 expression in primary bronchial epithelial
cells which results in an impaired regulation of inflammatory cytokines. Interestingly, COPD
patients had increased miR-125 levels, resulting in an impairment of not only A20 regulation
of inflammatory signalling, but also MAVS, thus reducing the patients antiviral response and
further worsening the condition of the patients [95]. However, when inhibiting the miRNA, there
was a more marked reduction in viral replication than of inflammatory markers, indicating that
miR-125a and b target MAVS preferentially to A20.
Critically, miR-19 has been identified to regulate several controllers of NF-κB, including SOCS3
[96], A20 and Rnf11 [40, 97], and CYLD [98]. Given the knowledge that miR-19 is a potent
regulator of inflammation in vitro, experiments must be done to assess its effect in vivo.
1.7 Cre recombinase
Cre recombinase technology is based on the use of the Cre recombinase enzyme, which recog-
nizes and recombines sequences of genomic DNA, called lox sites [99]. The LysMCre animal
was produced in 1999 to allow for myeloid specific deletion of genes [100]. Cre recombinase
is expressed upon activation of the Lyz2 promoter, activated specifically in macrophages and
monocytes. When bred with an animal with a gene flanked by specific lox sites, this allows
for cell specific gene deletion. When combined with the miR-17-92fl/fl, this should theoretically
provide a myeloid specific deletion of this miRNA cluster. This will hopefully mitigate the issue
of a full miR-17-92 cluster being fatal.
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2 Aims
As the miR-17-92 cluster has been shown to regulate NF-κB driven innate immune signalling,
it would be interesting to investigate wether this cluster has an effect in macrophages, a major
component of the innate immune response, and a critical determinable factor in disease. As
little investigative work has been done to elucidate this topic, this project intends to examine the
effect of the miR-17-92 on cytokine production and NF-κB signalling in macrophages. The aims
of this study are as follows:
• Generate a miR-17-92 mø specific transgenic animal.
• Investigate if the miR-17-92 cluster regulates cytokine production in Macrophages.
• Investigate if modulation of the miR-17-92 cluster affects the innate immune response in
vivo.
• Develop a Modular Nanostring Panel that can be used by multiple projects to assess
macrophage response by transcription.
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3 Materials and Methods
3.1 Software
Software Company
Adobe Illustrator CS6 Adobe
FloJo 10.3 FlowJo LLC
Geneious 8.1.5 Biomatters
ImageStudio 3.1.4 LI-COR
Microsoft Office for Mac 2016 Microsoft
nSolver 4.0 Nanostring Technologies, Inc.
Oligo7 Molecular Biology Insights, Inc.
Papers3 Digital Science and Research Solutions Inc.
Partek Genomics Suite 6.6 Partek, Inc.
Partek Flow Partek, Inc.
Prism6 GraphPad Software
LYX- LATEX document writer Free Software Foundation, Inc.
3.2 Media and buffers
LB medium
20g LB media Powder (Roth) in 1L water. Autoclaved and Ampicillin or Kanamycin added fresh.
LB agar
32g LB agar powder (Roth) in 1L water. Autoclaved and Ampicillin or Kanamycin added before
poured into clean petri dishes.
Complete DMEM
Gibco DMEM, High glucose, L-Glutamine (Thermo Fisher) with 10% (v/v) Heat-inactivated ster-
ile filtered FBS and 1% (v/v) penicillin and streptomycin.
ELISA washing buffer
0.01% (v/v) Tween20 (Roth) in 1x PBS.
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ELISA blocking buffer
0.01% (w/v) BSA in 1x PBS
MACS buffer
1% (w/v) BSA, 2mM EDTA in 1xPBS
Duplex buffer
Ingredient
Potassium Acetate 100mM
HEPES 30mM
Adjust pH to 7.5.
6x Laemllie lysis buffer
Ingredient
SDS 1.2g
Bromophenol Blue 6mg
Glycerol 4.7ml
1M TRIS pH6.8 1.2ml
Water 2.1ml
Dilute to 1x before use and add 50mM DTT and 1/1000 dilution of benzonase (Thermo Fisher).
MOPS buffer
NuPAGE 20x MOPS SDS running buffer (Thermo Fisher) diluted in water.
Transfer buffer
100ml 10x Tris-Glycine Buffer (Thermo Fisher), 150ml Methanol, 750ml water.
TBS-T
100ml 10x TBS (Thermo Fisher), 0.1% Tween20 (Roth) and 900ml water.
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iCLIP buffers
iCLIP cell lysis buffer
1M TRIS pH7 2.5ml
1M TRIS pH8 2.5ml
5M NaCl 2ml
10% Igepal 10ml
10% SDS 1ml
5% Sodium deoxycholate 10ml
Water 71ml
Add Protease inhibitors
iCLIP High Salt Wash
1M TRIS pH7 2.5ml
1M TRIS pH8 2.5ml
5M NaCl 20ml
10% Igepal 10ml
10% SDS 1ml
5% Sodium deoxycholate 10ml
Water 53ml
Add Protease inhibitors
PNK wash buffer
1M TRIS pH7 1ml
1M TRIS pH8 1ml
1M MgCl 1ml
10% Tween20 2ml
Water 95ml
5xPNK pH6.5 buffer
1M TRIS pH6.5 350µl
1M MgCl 50µl
1M DTT 5µl
Water 555µl
2xPK Buffer
1M TRIS pH7 10ml
1M TRIS pH8 10ml
5M NaCl 2ml
0.5M EDTA 4ml
Water 74ml
3.3 Mice
3.3.1 Breeding miR-17-92fl/fl - CD11b-Cre
CD11b-Cre mice were a kind gift from Prof. Andreas Zimmer. They were bred with a miR-17-
92fl/fl animal, purchased from Jax Laboratories (JAX stock #008458) [37]. An animal of the
progeny, miR-17-92fl/- Cd11b+/- were then bred with mir-17-9fl/fl mice, and then the progeny
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Primer name Sequence
miR-17-92fl fwd TCGAGTATCTGACAATGTGG
miR-17-92fl rev TAGCCAGAAGTTCCAAATTGG
CD11b-Cre fwd CATTTGGGCCAGCTAAACAT
CD11b-Cre rev CCCGGCAAAACAGGTAGTTA
LysMCre fwd CATTTGGGCCAGCTAAAC
LysMCre rev CCCGGCAAAACAGGTAGT
Table 1: Genotyping Primers
that are miR-17-92fl/fl - CD11b-Cre+/- are then kept by breeding with miR-17-92fl/fl. The progeny
of these are then used for experiments and maintaining the line. All breeding and housing was
performed at the Haus für Experimentelle Therapie (HET) at the Universität Klinikum Bonn.
3.3.2 Breeding miR-17-92fl/fl - LysMCre
LysM-Cre mice were a kind gift from Imgard Förster [100]. They were bred with a miR-17-92fl/fl
animal, purchased from Jax Laboratories (JAX stock #008458) [37]. An animal of the progeny,
miR-17-92fl/- LysM-Cre+/- were then bred with mir-17-9fl/fl mice, and then the progeny that
are miR-17-92fl/fl - LysM-Cre+/- are then kept by breeding with miR-17-92fl/fl. The progeny
of these are then used for experiments and maintaining the line. Genotyping was performed
using the primers in table 1, a WT animal for miR-17-92fl/fl was expected to have a band of
255bp, while a homozygous miR-17-92fl/fl animal has a band of 289bp. Genotyping for LysMCre
was performed with a simple positive or negative PCR, using the priers outlined in table 1.All
breeding and housing was performed at the Haus für Experimentelle Therapie (HET) at the
University Klinikum Bonn.
3.3.3 Animal sacrifice
Animals were handled as little as possible, and euthanased by cervical dislocation.
3.3.4 Peritoneal Cavity
Immediately following euthanasia, the fur was pulled away from the abdomen. To collect cy-
tokines from the cavity, 2ml of PBS+2mM EDTA was injected through the abdominal fat pad,
with care to avoid internal organs, the belly was shaken thoroughly, and then 1ml of fluid was
collected, spun down at 300g, and then transferred to a new 1.5ml Eppendorf tube and frozen.
Another 8ml of PBS+2mM EDTA was injected into the peritoneal cavity, shaken again and col-
lected, before the cell pellet from the previous collection is added. This suspension is spun and
then resuspended in DMEM +10%FCS +P/S, before counting and plating for adherent cells.
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If collection is only for peritoneal lavage cells, 10ml of PBS +2mM EDTA injected through the
abdominal fat pad, the belly is shaken, and then as much fluid is collected as possible. This is
spun down at 300g, and then resuspended in DMEM +10%FCS +P/S, before gross counting
and plating for adherent cells.
Alternatively, cells may be pelleted and subjected to MACS magnetic selection (3.3.8).
3.3.5 Spleen preparation
The spleen was removed from the mouse and then trimmed of as much fat as possible, and
placed in RPMI +0.1% FCS on ice until use. It is then crushed using a syringe plunger through
a 70µm cell strainer, and washed with 5-10ml RPMI+0.1% FCS. The suspension is spun at
300g for 8 minutes at 4˚C, then a red blood cell lysis is performed for 2 minutes following the
manufacturers instructions, before being stopped with PBS. The suspension is then spun at
300g again for 5 minutes at 4˚C, the supernatant is discarded, and the pellet is resuspended in
1ml MACS buffer. The suspension is then passed through a 40µm cell strainer, washed with
MACS buffer, and then spun again at 300g for 5 minutes. The cell pellet is then resuspended
with 200µl of MACS buffer per spleen, before proceeding to magnetic bead binding (3.3.8).
3.3.6 BMDM preparation
Femurs and tibias from 6 - 10 week old mice were isolated, the muscle and tissue was removed
and then briefly soaked in 70% ethanol. An end of the bone was cut and bone marrow was
flushed using a fine-gauge needle and DMEM supplemented with 10% FCS and pen/strep.
Bone marrow was collected, filtered through a 70 μm Nylon cell strainer, and pelleted (5 min
at 340 x g), resuspended in 40 ml of DMEM supplemented with either 20% L929 supernatant
or 40 ng/ml M-CSF (R&D Systems). BMDMs were differentiated over 7 days in 20 ml of media
in T175 flasks. Adherent BMDMs were harvested by removing media, washing cells in PBS
and then incubating cells at 4°C for 10 min in cold PBS supplemented with 2 % FCS and 2 mM
EDTA. Gentle tapping dislodged cells and scraping dislodged any remaining adherent cells.
Cells were collected, pelleted (5 min at 340 x g) and resuspended in DMEM with 10% FCS and
pen/strep and plated for experiments.
3.3.7 In vivo LPS injection
In accordance with ethics form 84-02.04.2014.A151, mice were injected with low dose LPS
(0.5µg per gram animal weight in 100µl of sterile PBS) or sterile PBS intraperitoneally. Ani-
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mals were monitored for temperature fluctuations and behavioral changes every 30 minutes
until 6 hours post-injection. Animals were then sacrificed by cervical dislocation, then spleen,
peritoneal lavage and leg bones were removed. The spleen was processed as per 3.3.5, peri-
toneal lavage as per 3.3.4, and leg bone as per 3.3.6 before being frozen at -80˚C. All in vivo
experiments were performed with the supervision of a certified animal handler.
3.3.8 MACS Cd11b and F4/80 cell magnetic selection
Cells from the peritoneum, spleen or blood were washed with MACS buffer, and incubated with
FC blocker (Miltenyi Biotec) for 10 minutes before incubation with CD11b microbeads (Miltenyi
Biotec) for a further 15 minutes. The cells are washed once with MACS buffer, before passing
through an MS column (peritoneum and blood) or LS column (spleen)(Miltenyi Biotec). The
column was washed twice with MACS buffer, before a plunger was used to extract the selected
cells, for downstream applications.
3.4 Cell Culture
3.4.1 Immortalised BMDMs
Immortalised BMDMs were generated as previously described[101]. Cells were grown in DMEM
with 10% FCS and antibiotics in flasks. Cells were passaged by removing media from adher-
ent cells, washing cells with PBS, then incubating adherent cells with Trypsin-EDTA (Invitro-
gen/Gibco) for 5 min at 37°C. Cells were then collected with addition of DMEM with 10% FCS
and antibiotics, spun in a centrifuge at 300g for 5 minutes, and diluted with fresh DMEM with
10% FCS and antibiotics in new flasks.
3.4.2 Immortalised MEFs
A pregnant mouse with embryos between 13.5 and 14.5 days was euthanized with CO2 as-
phyxiation, and the uterus was removed in a sterile hood to a dish with sterile BBS on ice. The
embryos were removed from the uterus and washed thoroughly with PBS, then the heads and
all red matter were removed. The remainder was finely minced with sterile scalpels and incu-
bated with Trypsin-EDTA for 5 minutes. DMEM with 10% FCS and antibiotics was added to stop
Trypsin reaction, the mixture was spun at 300g for 5 minutes, and then the cells were resus-
pended in fresh DMEM with 10% FCS and antibiotics, then incubated in a flask overnight. The
following day, adherent cells were washed with PBS, and then collected with Trypsin-EDTA,
before being plated into 2 wells of a 6 well plate, one diluted at 1/4 and the other well at 1/6
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dilution. 1µl GeneJuice transfection reagent was mixed with 2µg of SV40-T antigen expressing
plasmid (donated by Michael Gantier) in 100µl of Optimem for 20 minutes, before being added
to the MEF cells and incubated overnight. The next day, cells were washed with PBS and fresh
DMEM with 10% FCS and antibiotics was added. Cells were allowed to grow until confluent
and then split into flasks. After growth of cells in flasks is to confluency again, the cells are
immortalised and can be frozen and used for experiments.
3.4.3 MEF cells
MEF cells were grown in DMEM with 10% FCS and antibiotics in flasks. Cells were passaged
by removing media from adherent cells, washing cells with PBS, then incubating adherent cells
with Trypsin-EDTA (Invitrogen/Gibco) for 5 min at 37°C. Cells were then collected with addition
of DMEM with 10% FCS and antibiotics, spun in a centrifuge at 300g for 5 minutes, and diluted
with fresh DMEM with 10% FCS and antibiotics in new flasks.
3.4.4 Virus generation
4x105 HEK 293T cells were plated into a well of a 6 well plate, and left to rest overnight at 37˚C
in an incubator. The next day, cells were transfected with 100ng VSV-G plasmid, 1µg of gag-pol
plasmid, and 2µg of vector plasmid, using 8µl of GeneJuice transfection reagent and 110µl of
optimem. The following day, cells were observed for colour tag production (if any) to confirm
transfection, and media was removed and replaced with DMEM 30% FCS and antibiotics, then
left overnight at 37˚C in an incubator. The following day, the viral supernatant was collected
with a blunt needle and syringe, and filtered through a 0.45µm filter. This filtered supernatant
can now be used to infect a target cell. Plasmids maps are in Fig 3.
3.4.5 BMDM virus infection
BM of an animal is prepared as previously described in 3.3.6 and is plated into 3 T75 flasks.
2 days later, 10ml of viral supernatant from 3.4.4 is given to each flask, supplemented with
10ng/ml M-CSF or 20% volume L929 conditioned media, as desired. The following day, the
media is removed, and the cells are washed with PBS before replacing the media with normal
DMEM with 10% FCS, antibiotics, and M-CSF or L929 supplements. The BMDMS are allowed
to differentiate until day 7 after initial plating, collected as described in 3.3.6 and experiments
are performed.
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Figure 3:
Plasmid maps. Plasmids used to generate virus. See 3.4.4 for protocol used.
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Name Sequence
NC1 ZEN AMO 5’-GCGUAUUAUAGCCGAUUAACG-3’
miR-17-5p ZEN AMO 5’-CUACCUGCACUGUAAGCACUUU-3’
miR-18-5p ZEN AMO 5’-CUAUCUGCACUAGAUGCACCUU-3’
miR-19a-3p ZEN AMO 5’-UCAGUUUUGCAUAGAUUUGCAC-3’
miR-19b–1-3p ZEN AMO 5’-UCAGUUUUGCAUGGAUUUGCAC-3’
miR-92a-3p ZEN AMO 5’-ACAGGCCGGGACAAGUGCAAU-3’
RD 5’-UAACACGCGACAGGCCAACUU-3’
B-406AS-1 5’-UAAUUGGCGUCUGGCCUUCUU-3’
Table 2: AMO and immunostimulatory sequences.
3.4.6 AMOs and transfection
AMOs were purchased from Integrated DNA Technologies (IDT) with ZEN modifications to pre-
vent exonuclease digestion and 2′OMe modifications to each base. Stocks were stored at 50µM
in Duplex buffer, and diluted to 4µM before use. RD control ssRNA and B-406AS-1 are not made
with ZEN or 2’OMe modifications. RD and B-406AS-1 stocks are at 80µM.
AMOs were transfected into cells with DOTAP (Roche). AMO was first diluted in 32µl DMEM,
and 1.05µl DOTAP was mixed and incubated in 37µl DMEM in parallel, and incubated both
separately for 5 min. Mix both solutions and incubate for a further 10 minutes, before adding
25µl of this to a well of a 96 well plate, with 80x103 BMDMs in 150µl of DMEM.
To stimulate TLR7, mix 1.35µl of 80µM B-406AS-1 in 37µl DMEM, and 4.75µl DOTAP in 33µl
DMEM in parallel, and incubate both separately for 5 minutes. Mix both together, incubate for
a further 10 minutes, before adding 25µl to a well of a 96 well plate with BMDMs and AMOs.
MEF cells were transfected using a reverse transfection method. 1.35µl Lipofectamine 2000
(Invitrogen) was diluted in 150µl Optimem and 1.5µl of 4µM AMO was added. This mixture is
incubated for 20 minutes, before 50µl was pipetted per well of a 96 well plate. Then 150µl of
DMEM with 8x103 MEF cells were pipetted on top, and incubated overnight in an incubator.
3.4.7 Actinomycin D
Cells were cultured as previously described (3.3.6) and stimulated with LPS for indicated times.
Actinomycin D (Sigma) was diluted for a final concentration of 5µg/ml in media and LPS was
incubated with the cells for the indicated times.
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3.5 Biochemistry
3.5.1 ELISAs
Mouse IL-6 and TNFa ELISAs were purchased from BD Biosciences. NUNC Maxisorp plates
were coated with 50 μl Capture antibody diluted in PBS overnight at room temperature. Plates
were blocked with 1% BSA in PBS for 1 hour, then supernatants and standard dilutions were
added for 2 hours at room temperature. 50µl of detection antibody in 1% BSA PBS were then
incubated for a further 2 hours, before a working dilution of 50µl Streptavidin-HRP in 1% BSA
PBS was added for 20 minutes. Between each step, plates were washed with 0.05% TWEEN-
20 PBS using an automated washer. 50µl of TMB substrate was used to develop the ELISA,
and the reaction was stopped with 1M Sulfuric Acid and absorbances at 450nm and 570nm
were read using a Spectramax i3.
3.5.2 Western blots
Protein lysates were prepared from cells using RIPA or laemmli buffer, supplemented with phos-
stop and proteinase inhibitors (Sigma-Aldrich). Lysates were frozen at -20˚C for storage, and
were then thawed on ice for use. Supernatants were spun at maximum speed, 4˚C in a cen-
trifuge to pellet nucleic acid material. If lysed with RIPA, the protein diluents were added to
appropriate dilutions of NuPAGE LDS buffer (4x) and Reducing agent (10x). The lysates of ei-
ther laemmli or RIPA are then heated at 90˚C for 10 minutes. Heated protein lysates were then
loaded into well of a NuPAGE™ 4-12% BIS-TRIS gels (Invitrogen), and run using MOPS running
buffer, at 100v for ~1.5-2 hours, or until the protein front reached the bottom of the gel in a XCell
SureLock™ Mini-Cell Electrophoresis System (Invitrogen). Ladder used was a PageRuler™
Plus Pre-statined Protein (ThermoFisher). The separeted proteins were then transferred to a
PVDF membrane using a wet TRIS-Glycine transfer system in an XCell II™blot module (Invit-
rogen), at 32V for 1.5 hours. Membranes were then blocked with 3% BSA TBS for 1 hour at
room temperature, before incubation with primary antibodies overnight at 4˚C. Membranes were
washed with 0.1% TWEEN-20 TBS before incubation with a fluorescent secondary antibody for
2 hours. Membranes were washed again and then imaged using a LI-COR Odyssey device.
Quantification was performed using the ImageStudioLite software from LI-COR. For antibodies
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Antibody name Company Product no. Use
A20/TNFAIP3 (D13H3) Rabbit mAb Cell Signaling 5630S Western Primary
β-Actin Mouse Monoclonal Antibody Li-Cor 926-42212 Western Primary
Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb Cell Signaling 3033S Western Primary
IRDye 800CW Donkey Anti-Rabbit IgG (H+L) Li-Cor 926-32213 Western Secondary
IRDye 680LT Goat anti-Mouse IgM (mu chain specific), 0.1 mg Li-Cor 925-68080 Western Secondary
Anti-NK1.1-APC, mouse Miltenyi Biotec 130-095-869 FACS
BV510 Rat Anti-Mouse B220/CD45R Clone RA3-6B2 BD 563103 FACS
CD8a-FITC, mouse (CD8) Miltenyi 130-091-605 FACS
Anti-Mouse CD3e PE-Cyanine7 eBioscience 25-0031-81 FACS
CD4 Monoclonal Antibody (OKT4 (OKT-4)), PerCP-Cyanine5.5 eBioscience 45-0048-42 FACS
BV421 Rat Anti-Mouse CD62L Clone MEL-14 BD 562910 FACS
APC-Cy7 Rat Anti-Mouse CD16/CD32 Clone 2.4G2 BD 560541 FACS
PerCP-Cy™5.5 Rat Anti-Mouse Ly-6C Clone AL-21 BD 560525 FACS
Pe/Cy7 anti-mouse Ly6G (1A8) Biolegend 127618 FACS
Anti-Mouse CD11b PE eBioscience 12-0112-81 FACS
BV421 Armenian Hamster Anti-Mouse CD11c Clone N418 BD 565451 FACS
Anti-mouse I-A/I-E (MHCII) (clone M5/114.15.2) Biolegend 107627 FACS
Table 3: FACS and Western Blot Antibodies
used, refer to table 3.
3.5.3 CTB assay
CellTiter-Blue® Cell Viability Assay (Promega) was aliquoted and stored at -20˚C. 10µl of CTB
reagent was diluted in 50µl of Complete DMEM per well of a 96 well plate. To perform the assay,
media was removed from the cells in culture, and 50µl of diluted CTB reagent/Complete DMEM
was put onto the cells. Cells were incubated for a further 1 hour at 37˚C before measuring the
fluorescence with excitation of 560nm and emission of 590nm.
3.5.4 Seahorse cellular metabolism assay
Cells were plated into a special Agilent Seahorse XF 96-well plate, and treated according to
the experiment. The cells are then washed thoroughly three times with assay medium, before
resting for 1 hour in a non-carbonated incubator. The 4-port injector plate is prepared with 20µl
100mM Glucose, 22µl oligomycin, 25µl FCCP and 27µl Antimycin A / Rotenone. Assay was
performed on a Agilent Seahorse XFe96. Thanks to Mario Lauterbach for operating the device.
For the analysis, the average of the three readings between treatments was used. For Basal
Glycolysis: ECAR(Glucose-null), glycolytic capacity: ECAR(Glucose-null), Spare glycolytic re-
serve: ECAR(oligo-glucose), ATP production: OCR(null-oligo), Maximum respiration: OCR(FCCP-
AA/ROT), Basal Respiration: OCR(null-AA/ROT).
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3.5.5 Magpix multiplex cytokine assay
Samples were diluted 1:1 with with universal assay buffer, with guidance from Christian Kolbe
and Mario Lauterbach. Beads coated in antibodies were washed twice before incubating with
either the standard or with diluted samples. After a 2 hour incubation, 100µl of detection antibody
mix was added to each well, and incubated for a half an hour. Streptavidin-PE was then added
to the beads, and incubated for half an hour again, before being washed, resuspended and then
detected on a Luminex MAGPIX®
3.6 RNA, cDNA and qRT-PCR
3.6.1 RNA preparation
Samples are lysed using 350µl of Qiazol, and homogenised, before freezing at -80˚C. Frozen
samples are thawed and then RNA is isolated using the miRNeasy kit (Qiagen) following the
manufacturers instructions, and gDNA is digested using the on column DNAse protocol of Qia-
gen.
3.6.2 mRNA cDNA preparation
500ng of RNA per sample, or a pool of all samples is mixed in a volume of 12.9µl with 1µl of
Oligo dT, and put on a thermocycler for 5 minutes at 65˚C, before being moved back to ice for
2 minutes. Then, 4µl of 5x First strand buffer, 1µl 10mM dNTPs, 1µl 0.1M DTT, and 0.2µl Su-
perScript III are mixed in. The sample is put back onto the thermocycler at 50˚C for 50 minutes,
85˚C for 5 minutes and then put back on ice. cDNA is then diluted 1:10 with nuclease free water.
qRT-PCR was performed using 5µl Maxima SYBR Green/ROX qPCR Master Mix, 2µl of mixed
2µM forward and reverse gene-specific primers, 1µl of nuclease free water, and 2µl of diluted
cDNA. qPCR was performed in 10µl reactions, following the manufacturers instructions using a
QuantStudio 6 Flex Real-Time PCR System from Applied Biosystems.
3.6.3 miRNA cDNA and RT-qPCR
miRNA cDNA was generated using a modified protocol of the Taqman® small RNA Assays
protocol from Applied Biosystems. 1µl of up to 3 stem-loop miRNA RT primers were mixed
together with Multiscribe Reverse Transcriptase (Applied Biosystems), 1.5µl of 10x buffer and
10ng of total RNA.
qPCR was performed in 10µl reactions, following the manufacturers instructions using a QuantStu-
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Primer Name Sequence
mTnfaip3_RT_For TGCCCACAGTTCCGAGAGAT
mTnfaip3_RT_Rev TGAGGCAGTTTCCATCACCA
mFbxl11_RT_For TTGCTGACTCCACCCACAGA
mRbxl11_RT_Rev GAGACAAAAGGGGCATGTGG
mRnf11_RT_For GCTTTCTTCCTCCCGCAGAT
mRnf11_RT_Rev GACTCGTGAAGCAGGGAGATG
mAtg16l1-RT-Fwd CTGGATTCAAATGCGGCTCT
mAtg16l1-RT-Rev TTCCCTGTCAGCACACTCCA
mIl-10_RT_For AAGCATGGCCCAGAAATCAA
mIl-10_RT_Rev TCACAGGGGAGAAATCGATGA
mIl-1b_RT_For TTGACGGACCCCAAAAGATG
mIl-1b_RT_Rev CAGCTTCTCCACAGCCACAA
mTnfa_RT_For CCAAATGGCCTCCCTCTCAT
mTnfa_RT_Rev TGGTGGTTTGCTACGACGTG
Primer Name Sequence
mIl-6_RT_For CAAAGCCAGAGTCCTTCAGAG
mIl-6_RT_Rev GTCCTTAGCCACTCCTTCTG
mCxcl1_RT_For ATGGCTGGGATTCACCTCAA
mCxcl1_RT_Rev AGGGAGCTTCAGGGTCAAGG
pri-miR-155-RT_For AAACCAGGAAGGGGAAGTGT
pri-miR-155-RT_Rev ATCCAGCAGGGTGACTCTTG
pri-miR-146a-RT_For GTGTGTATCCCCAGCTCTGA
pri-miR-146a-RT_Rev CTTCACCCCACTCTCTCCAC
mHprt_RT_For TGAAGTACTCATTATAGTCAAGGGCA
mHprt_RT_Rev CTGGTGAAAAGGACCTCTCG
Cre_RT_For GTTCACTCATGGAAAATAGC
Cre_RT_Rev TATCTTTAACCCTGATCCTG
mMir17hg_RT_For ACAGAGCTAAAGTTTTCCAT
mMir17hg_RT_Rev AATTCTGGTCACTCACAATC
Table 4: qRT-PCR Primers
dio 6 Flex Real-Time PCR System from Applied Biosystems. A list of qRT-PCR primers is found
in Table 4.
3.6.4 Lexogen 3’ sequencing.
Samples were prepared using the QuantSeq 3’ mRNA-Seq Library Prep Kit FWD for Illumina
(Lexogen) by the NGS Core Facility, Institute of Human Genetics, Division of Genomics at the
university of Bonn. Sequencing was performed to 20 million reads per sample, and data was
analysed using Partek Flow. The pipeline for the analysis was provided by Dr Simit Patel,
Partek. Briefly, the reads provided with the adapters trimmed from the NGS Core Facility, then
were aligned using STAR 2.5.3a, the genes and transcripts were quantificed to Ensemble mm10
whole genome, and the normalisation and analysis was performed using DESeq2[102]. Genes
with ≤1 read count were excluded from further analysis. Volcano plots were created using FDR-
stepup corrected p-values.
3.7 Nanostring
3.7.1 Nanostring Elements
Master stocks of Probes A and B were prepared according to the Manufacturer’s guidelines. 5µl
of each Probe A stock (1µM) or Probe B (5µM) were pipetted, and TE buffer was added to make
a final volume of 1ml. 2µl of this was aliquoted into microfuge tubes and frozen at -80˚C as single
use tubes, yielding a final concentration in the Master Probe A stock of 5nM each, and 25nM in
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the Master Probe B stock. For each set of 12 samples, 14.5µl of 0.1% TE-TWEEN was added
to the aliquoted Master Probe A and B stocks, which are now at 30x Working concentrations of
20pM and 3nM respectively.
3µl of total cell lysate (10,000 mouse BMDMs, or 20,000 human PBMCs per µl) in RLT buffer with
βME, or 100ng of total RNA extracted using the miRNeasy kit (Qiagen) was incubated with 13µl
of 30x Working Probe A and 13µl of 30x Working Probe B, with hybridisation buffer, following
the manufacturer’s instructions for 24 hours at 67˚C, and a lid temperature of 72˚C. 24 hours
was chosen because the manufacturer’s Package Insert claims and increase of 5% in target
counts per hour up to 24 hours without increase in background signal1. Following hybridisation
the samples were moved to the Nanostring Prep Station immediately for processing.
3.7.2 Nanostring miRNA
100ng of total RNA was prepared as outlined in 3.6.1 and then diluted to 33ng/µl using nuclease
free water. miRNAs were then hybridized and ligated to nCounter miRNA Tag Reagents as
per the manufacturer’s instructions. Following ligation, the samples are then hybridized with
the Reporter CodeSet and Capture ProbeSet for a minimum of 16 hours, before immediately
proceeding to use the Nanostring Prep Station.
3.8 Nanostring Normalisation and Data processing
3.8.1 Nanostring Elements
Analysis was done using the nSolver 4.0 (alpha build) software, a gift from Dr Maik Pruess of
Nanostring. Raw data was imported as .RCC files, and data was manually inspected for quality
control flags, binding density and technical performance before proceeding. Background sub-
traction was performed using the geometric mean of included negative controls. Then positive
Control Normalisation was done using the geometric mean of the positive controls (for techni-
cal normalisation of the samples for assay performance), and then finally Content normalisation
was done using Rpl19, Hprt, Actb, Gapdh, and Eef1g.
1nCounter Elements General Purpose Reagents Package Insert, Version 03, created 2013-12, Ref LBL-C0266-
03.
35
Data was then exported from nSolver 4.0 (alpha build) software as log2 counts, and then
opened in Microsoft Excel. Removal of low counts before analysis was done previously by
other groups[103]. For the purposes of our own analysis, a mean of the values for a gene
across all samples was identified, and all genes with an average detection below the highest
negative control were excluded from subsequent analysis. Furthermore, all ratio-metric com-
parisons of unstimulated to stimulated conditions must take into account if the gene was not
detected in unstimulated conditions (such as Il-6 and Il-1b).
3.8.2 Nanostring miRNA
Analysis was done using the nSolver 4.0 (alpha build) software, a gift from Dr Maik Pruess of
Nanostring. Raw data was imported as .RCC files, and data was manually inspected for quality
control flags, binding density and technical performance before proceeding. Background sub-
traction was performed using the geometric mean of included negative controls. Then positive
Control Normalisation was done using the geometric mean of the positive controls (for techni-
cal normalisation of the samples for assay performance), and then finally Content normalisation
was done using the geometric means of the included Reference genes; Actb, B2m, Gapdh and
Rpl19.
Data was then exported from nSolver 4.0 (alpha build) as log2 counts and ranked according to
expression in the WT samples. Batch correction was performed in Partek for date of processing.
3.8.3 Partek Analysis
Log2 counts of data is imported to Partek, PCA analysis is performed for uniformity of data,
and batch corrections made if necessary. Two-way ANOVA was performed, and multiple test
corrected using FDR step-up. Volcano plots were then created with these p-values.
3.8.4 Partek miRNA analysis
Log2 counts of data is imported to Partek, PCA analysis is performed for uniformity of data, and
batch corrections made if necessary. Batch corrected data was exported to Prism for graphing
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of individual miRNA, and analysis using Tukey’s multiple correction test. In Partek, two-way
ANOVA was performed, and multiple test corrected using FDR step-up, for all conditions. Vol-
cano plots were then created with these p-values. miRNA lists were created from analysis of
interest, and a gene list is created using Partek’s in-built feature to search Targetscan.org for
predicted targets of miRNA identified in the list. This gene list is then used in Partek to search
for pathway enrichment.
3.9 iCLIP
The original protocol is from Huppertz et al[104], and adapted by Tim Sadlon. Minor alterations
were made with guidance by Dr Kate Jeffrey.
In brief, 3x107cells were cross-linked with UV irradiation (Biol-link 254, Vilber), collected, and
the cell pellet was frozen. The pellet was lysed and treated with RNAse I briefly to shorten RNA
molecules, before immediately stopping. Samples were then immunoprecipatated with Dyn-
abeads™ Protein A (ThermoFisher, 10001D) with Pan-AGO antibody (Diagenode, Clone 2A8,
C15200167) or IgG control (Jackson Immunoresearch, 315-005-008). Cross-linked immuno-
precipitated RNA was then 3’ de-phosphorylated and an L3 adaptor ligated. The 5’ end was
labelled with 32p-γATP, and a western blot was performed using a 4-12% BIS-TRIS gel. The
protein as cross-linked RNA were transferred to a nitrocellulose membrane before phosphor-
imaging to ensure transfer. Using the image as a guide, small sections of each sample were
cut out of the membrane corresponding to the weight of AGO, and treated with proteinase K
to digest the protein and release the RNA from the membrane. The RNA is then isolated and
cDNA is made using RT primers containing Illumina sequencing barcodes. The cDNA is then
purified using a urea gel, before circularising the cDNA, and then incubated with Cut_oligo to
form a double-stranded molecule over an inserted BamHI site. This BamHI site is then cleaved,
and the newly linearized cDNA libraries can then amplified and sent for sequencing.
37
Sequence Name Sequence
RT -2 5’Phos/NNACAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC
RT -6 5’Phos/NNCCGGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC
RT -10 5’Phos/NNGACCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC
RT -15 5’Phos/NNTATTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC
Cut_oligo GTTCAGGATCCACGACGCTCTTCaaaa
P5 5’-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT-3’
P3 5’-CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT-3’
L3 adaptor 5rApp/AGATCGGAAGAGCGGTTCAG/3ddC/
Table 5: Sequences used for iCLIP.
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4 Results
4.1 Decrease of Cytokines following miR-17-92 modulation
miR-19 of the miR-17-92 cluster has been previously shown to inhibit many regulators of NF-
κB and inflammation [40, 96, 42]. In silico analysis of miRNA interaction between members of
the miR-17-92 cluster and other known regulators of inflammation indicate that the majority of
regulation is likely due to miR-19. To get an idea of the scale of potential regulation by the miR-
17-92 cluster of genes involved in inflammation in mouse, the predicted targets of each family
of the cluster was collected from TargetscanMouse and compiled in the table 6. By filtering
for genes with known regulatory effects of inflammation, it becomes clear that any effect will
be mostly driven by miR-19 and miR-17 families of miRNA. While it is important to note that
these are in silico predictions, many interactions have already been published (indicated by the
*, further references in Supplementary Table 9). Of important note, most of these publications
featured regulating these miRNA families in B cells, T cells and epithelial cells mostly, or showed
data that was cell-agnostic by using artificial means such as luciferase assays to indicate gene
regulation by miRNA.This has led to a shift in focus from expecting the physiological effect
of a miRNA being related to modulation of a single gene to understanding that it is likely the
augmentative effect of a miRNA regulating many genes within a pathway [40].
To confirm that decreasing the levels of miR-17 and miR-19 could also decrease the release of
cytokines, MEF cells were transfected with AMOs against miR-17, miR-19a and -19b, or non-
targeting control, and then stimulated with low doses of either LPS or PAM3csk4, previously
found to be the EC50 dose for these cells. Figure 4 shows that IL6 release was reduced, and
the cell viability was not affected by transfection of AMOs. Importantly, this is the first indica-
tion that the response to TLR4 is also reduced, indicating that, with previous results from TNF
stimulation, the modulation of response by miRNA is not receptor specific, but rather affecting
multiple mechanisms of NF-κB activation. There is also no significant modulation of cell viability,
if ever the cells are more viable when the miRNA are inhibited.
To further investigate this, differentiating miR-17-92fl/fl BMDMs were infected with virus ex-
pressing Cre recombinase to induce recombination of the miR-17-92 cluster, and were grown
for a further 4 days to allow for reduction of mature miRNA, as it has been shown that mature
miRNA are very stable and require several days to be reduced significantly [106]. Stimulation
with several TLR ligands resulted in reduced release of Tnfα, compared to control virus infected
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Tnfaip3
Rnf11
Fbxl11
Cyld
Atg16l1
Otud7b
Tnip1
Itch
miR-17/20a miR-18a miR-19a/b miR-92a
Zfand5
Ikzf1
Socs1
Socs3
Tax1bp1
Hif1a
Pten
Socs5
Fxr1
S1pr1
Bcl2l11
Socs6
Klhl20
n n n
1 1 1
2
1 1 1 1 2
12
1 1 2
1
1
1 1
1
1
1 1
1 1 1
4
2 1 1 1
1 3 1 12
12 1 1 1 1 1
1 2 2 12 1 1 1
1 2 1 1 1
1 2 1 2 1 1
1 1 3 2 1 1
2 3 2 1 12
8mer 7mer 6mer
*
*
*
*
*
*
*
*
*
*
*
*
*
*
1
Zfand6 1
Zfand4 1
Ikzf4* 11 1 3 1
Table 6:
Targetscan predicted targeting by the miR-17-92 cluster. A representation of regulators of
NF-κB and inflammation are targeted by various members of the miR-17-92 cluster. The number
and strength of the MRE is represented from Targetscan data [105], including both conserved
and non-conserved sites within the mouse transcriptome used only. Validated targets of one or
more members of the miR-17-92 cluster are marked with an *. See Table 9 for references.
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Figure 4:
Modulation of IL6 fromMEF cells with reducedmiRNA. A. IL-6 measured from supernatants
following stimulation with LPS or PAM3csk4. Both raw and fold change are depicted here.
B. CTB assay was performed to measure cell viability. Values are means with SEM of three
independent experiments. Two-way ANOVA was performed comparing the RD control, with
Dunnett’s multiple comparisons test, and an alpha set to 0.05.
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Figure 5:
Reduced mTnfα release from miR-17-92fl/fl-Cre BMDMs. A. Tnfα release from BMDMs
following miR-17-92fl recombination. BM was differentiated in M-CSF media after infection with
either Cre-recombinase virus or mCitrine control virus with and stimulated for 8 hours. B. miR-
19a expression from samples in A. Mean and SEM of 3 independent experiments. Two-way
ANOVA was performed, with Dunnett’s multiple comparisons test, and an alpha set to 0.05.
miR-17-92fl cells (Figure 5).
4.2 Generation of miR-17-92 mø-specific transgenic mice.
4.2.1 CD11b-Cre
The miR-17-92 cluster is a critical cluster for growth and development of an organism. This was
demonstrated by the initial attempt to make a KO mouse, where mice born as miR-17-92-/- died
within minutes of birth, with hypoplasia of the heart and lungs [37]. This raises several points
about the critical role that this miRNA cluster plays in the development of an organism, and
not just its role in cancer or immunity. In order to modify the expression of these miRNA after
birth of the animal, a Cre-recombinase approach was employed. The most obvious, allowing
for any cell in the body would be an inducible-cre model, such as the Esr1Cre. Unfortunately,
tamoxifen has known interactions with the immune system, and so the Esr1Cre animal would
likely have non-specific effects when generating a model for immune specific model [107, 108].
It was therefore decided to use the CD11b-Cre model, which would allow for the observation of
miRNA modulation in macrophages and microglial cells [109].
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To breed these animals, miR-17-92fl/fl mice was paired with a Cd11b-Cre mouse, both of the
BL/6 backgrounds. Then, using the miR-17-92+/fl- Cd11b-Cre+/- of the F1 generation to then
breed back with the miR-17-92fl/flresulted in 50% of the F2 generation with a homozygous ex-
pression for miR-17-92fl/fl , and of those, half were CD11b-Cre+/-. These mice were use for
further breeding with mice of the miR-17-92fl/flbackground, and Cd11b-Cre was kept to het-
erozygous expression in only 50% of the offspring. This would allow for the generation of mice
that could be littermate controls to miR-17-92fl/fl- Cd11b-Cre+/-mice. Furthermore, by design,
the level of Cre recombinase is kept to a minimum to avoid known Cre toxicity effects [110, 111].
However, initial testing of the mice BMDMs indicated that there was no deletion of the miR-
17-92 cluster, as there were equivalent mature miRNA amounts between either CD11b-Cre+
mice, and their CD11b-Cre- littermates. The cells were then tested for the expression of Cre
recombinase and there is no discernible difference between the two mice, indicating that the
lack of Cre expression is the cause of the fault. Figure 6 show that the levels of miRNA were the
same when tested by qPCR, and that there is a lack of Cre expression, especially compared
to the later generated miR-17-92fl/fl - LysMCre mice. These results were echoed by a study
published subsequently from another group attempting to measure Cre recombinase genetic
manipulation using the CD11b-Cre transgenic mice, indicating that it is a unreliable model for
myeloid specific deletion of target genes [112]. In conclusion, the CD11b-Cre model was unable
to delete the miR-17-92 cluster in BMDMs, and so what not used further.
4.2.2 miR-17-92fl/fl - LysMCre
After failing to successfully produce macrophages with a reduced miR-17-92 expression using
the CD11b-Cre mice, a new breeding program was set up using the well established LysM-
Cre mouse. While this model will not allow for myeloid deletion of the miR-17-92 cluster, it
has been used successfully in several other miRNA studies [66]. Breeding followed the same
pattern and reasoning as the miR-17-92fl/fl - CD11b-Cre+/- animals, (hereafter referred to as
miR-17-92∆, and littermate controls as WT, unless otherwise stated) with the F2 generation
being used to maintain the line for experiments. This new animal genotype was much more
successful at deleting the miR-17-92 cluster in BMDMs and in peritoneal cells, as shown in
figure 7. Interestingly, the effectiveness of Cre-driven miRNA deletion appeared to be more
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A B
Figure 6:
Expression of miRNA and Cre recombinase in CD11b-Cre expressing BMDMs. A. The
expression of mature miRNA from BMDMs from miR-17-92fl/Cd11b-Cre and littermate control
mice was determined with qPCR. The expression of miRNA was not significantly different be-
tween the two genotypes, indicating that the miRNA expression was unchanged in the CD11b-
Cre mice. B. The expression of Cre recombinase mRNA was determined using qPCR, and
using LysM-Cre expressing mice as positive controls, it is evident that the CD11b-Cre BMDMs
did not express Cre recombinase, hence had not recombined the miR-17-92fl locus.
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Figure 7:
miRNA expression in miR-17-92fl/fl∆ Macrophages. Expression of miRNA determined by
qPCR of BMDMs and Peritoneal cells and bone marrow, showing steady deletion of the miRNA
cluster. Data is of 3 independent experiments, with data normalised to the WT.
complete in the peritoneal cells than in the BMDMs. This may be in part due to how old the
cells are. As previously noted, mature miRNA are often long-lived molecules, and so when
deleted, may take several days to be reduced further, not to mention that Cre-recombination in
an incomplete activity [113, 106, 114].
When investigating the kinetics of miRNA deletion using LysM-Cre, it was noted that the ex-
pression of several miRNA from the miR-17-92 cluster were not changed in the bone marrow
of mice, but rather only after differentiation into BMDMs using L929 conditioned media. Fig-
ure 8 outlines this transition, and also shows that the expression of miR-19b and miR-92 are
decreased slightly in the WT BMDMs compared to their progenitor bone marrow. This is ex-
pected, as is has been previously published that the expression of the miR-17-92 cluster must
be down-regulated in a PU.1-dependant manner for proper macrophage maturation [115].
Mice were also born with normal ratio of genders and with normal ratio of LysM-Cre+/- to -/- mice,
with a slight tendency towards LsyM-Cre-/-. No developmental abnormalities were observed,
mice behaved the same, and no visual differences could be detected between mice.
Next, to investigate the specificity of deletion in tissues, the blood, spleen and peritoneal lavage
were harvested from mice and digested to single cells suspensions if necessary, before mag-
netically enriching CD11b+ cells. miR-17 was used as a measure of miRNA deletion from the
cluster, and it was noted that there was no observable difference between the mice in the blood
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Figure 8:
Expression of miRNA decreased following differentiation of BM to BMDMs. Using L929
conditioned media to induce BM HSC to BMDM differentiation reduced the expression of miRNA
of the miR-17-92 cluster, whereas M-CSF does not change them, other than miR-92. LysM-Cre
however does not delete the miRNA in BM, and is only activated upon differentiation of cells
to BMDMs. Mann-Whitney U test between BM and BMDMs of each genotype are performed,
*P<0.05, **P<0.01, ***P<0.001 ****P< 0.0001
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Figure 9:
Distribution of mice in litters. Data from 33 litters. A. Distribution of animals in the whole
population, with a nearly 50% distribution of animals between both gender and genotypes, in-
dicating that the mi-17-92fl/fl-LysM-Cre genotype does not confer a advantage to survival. B.
Distribution of mice within litters, represented as a percentage. There is no significant difference
between the distribution of female and male mice inside litters, however, more litters had a total
of wt mice within them.
46
Pe
rit
on
ea
l
Bl
oo
d
Sp
lee
n
0.0
0.5
1.0
1.5
2.0
2.5
Ratio expression of miR-17 from mice
R
at
io
 e
xp
re
ss
io
n
WT
miR-17-92Δ
*
Figure 10:
LysM-Cre drivenmiRNAdeletion is specific to peritoneal cells in vivo. Whole blood, spleen
or peritoneal lavage cells were selected with CD11b magnetic beads, and lysed for miRNA.
qPCR for mature miR-17 was performed, and ratio expression is represented here to WT peri-
toneal samples. Unpaired T-tests were performed, with correction for multiple comparisons
using the Holm-Sidak method.
or spleen compartments. It is entirely possible that given the mice are housed in a clean facility,
mø of the spleen and circulating in the blood have not had a significant enough NF-κB activation
to induce LysM expression, and by extent, LysM-Cre [116].
Investigating the cell composition of the spleen did not produce any significant differences, with
perhaps slightly lower, yet insignificant amounts of T-cells and macrophages.
4.3 Response of miR-17-92∆ BMDMs
4.3.1 Immortalisation of miR-17-92KO cell lines.
To investigate the role of the miR-17-92 cluster in macrophages, some BMDMs were harvested
from two sibling mice, one miR-17-92fl/fl (WT) and the other miR-17-92fl/fl - LysM-Cre -/+ (KO).
The cells are then grown in DMEM with 40ng/ml M-CSF initially, and infected with the J2Cre
virus [117], to immortalise them. In Figure 12, at the beginning of the immortalisation process
while the cells were still dependent on growth factors, the cells displayed a ~50% reduction in
mature miRNA of the floxed cluster. However, after weening the cells off extra growth factors,
the miRNA levels had equalised between the two cell populations. Genotyping of both cell
types indicated that they were still the correct genotype, and the cells had not been cross-
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Figure 11:
FACS analysis of spleen from WT and miR-17-92∆mice. Spleens were taken of WT and
miR-17-92∆mice, and were analysed for cellular composition. No distinct differences are seen.
FACS experiment performed by Dr Bianca Martin, analysis by H. James Stunden.
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contaminated (Figure 12C). Furthermore, the expression of Cre recombinase was reduced in
the immortalised cells when compared to freshly prepared BMDMs (7 days, M-CSF)(Figure
12D). This is likely connected to either the fact that cre-recombinase is toxic to cells in high
concentration, and that prolonged expression has caused some genetic damage [110, 111], or
that deletion of the miR-17-92 cluster is incompatible with life, even at the cellular level. This
has also been previously observed, where cre-driven deletion of the miR-17-92 cluster resulted
in proliferation defects [42]. As these cells were not viable, further experiments were performed
using primary cells only.
To investigate the release of cytokines, BMDMs were differentiated with M-CSF, as this gave
the greatest difference between genotypes (Figure8), and cells were stimulated with EC50doses
of LPS, R848, PAM3csk4 or CpG to stimulate TLR4, TLR7/8, TLR2 or TLR9 respectively. Sur-
prisingly, there was very little difference between the two genotypes, with mildly enhanced Tnfα
production, but no difference in the release of either IL-6 nor IL-12 (Figure 13). It has been
shown that Tnfα is a target of miR-19 [118, 42], and this would explain that Tnfα is higher, it was
not fully clear why there was no difference in IL-6 or IL-12 release. To confirm that there isn’t
a kinetics difference that cause these results, BMDMs were stimulated over the course of 24
hours and gene expression was measured by qPCR. By measuring both early and late stage
NF-κB induced genes, there was no discernible difference observed between the WT and miR-
17-92∆ BMDMs (Figure 14). One interesting observation is that the expression of the Mir17HG
is enhanced in the miR-17-92∆ BMDMs. It is possible that the cells are responding to a reduced
expression of the mature miRNA, and are attempting to express more. Furthermore, while ob-
served in the miR-17-92∆ cells, the expression pattern is decreased, potentially indicating that
the expression is to be reduced following stimulation anyway, in order to not regulate expres-
sion of NF-κB regulating genes, including Tnfaip3. Furthermore, known targets of the miR-19
do not show enhanced stability once translation is inhibited by actinomycin D. This implies that
miR-19 does not significantly regulate Tnfaip3, Rnf11 or Fbxl11 in macrophages.
Data shown in Figure 19 and table 7 indicates that only the miRNA of the miR-17-92 cluster are
largely adjusted following cre recombinase deletion of the cluster in BMDMs. This potentially
means that the current model is useful to determine the effects of this miRNA cluster alone.
However, there is still a large amount of mature miRNA of the miR-17-92 cluster present, even
after LysM-Cre deletion. Given that LysM-Cre is only activated during differentiation of bone
marrow with growth factors into macrophages, and these miRNA are present at equal levels in
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miRNA levels of miR-17-92 cluster and Cre recombinase in immortalised macrophages.
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Figure 12:
Immortalisation of miR-17-92∆ BMDMs. miRNA and Cre recombinase RNA levels in immor-
talised BMDMs of the miR-17-92∆ mice changed during the immortalisation process. A. Levels
of mature miR-17 and miR-19a determined by qPCR in the early stages of BMDM immortalisa-
tion and after the cells were immortalised. Unpaired T-tests were performed, with correction for
multiple comparisons using the Holm-Sidak method. B. Genotyping of immortalised BMDMs
showed that the cells were of the correct genotype, and were not incorrectly prepared. C. A fold
change of Cre recombinase mRNA determined by qPCR, comparing the immortalised BMDMs
to freshly prepared BMDMS. ND=Not detected.
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Figure 13:
Release of Cytokines from BMDMs. BMDMS were stimulated for 6 hours with different TLR
ligands and supernatants were collected for cytokine analysis with ELISA. No statistically sig-
nificant differences were found between WT and miR-17-92∆ stimulated BMDMs. Mean ± SEM
of 3 independent experiments (each performed in pairs).
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Figure 14:
mRNA kinetics following stimulation. Stimulation of primary BMDMs with LPS showed no
difference in the kinetics of gene expression between miR-17-92∆ and littermate controls. Val-
ues graphed are expression normalised with Hprt.
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Figure 15:
Actinomycin D RNA stability. BMDMs were stimulated for 3 hours with LPS and then treated
with Actinomycin D to inhibit mRNA production for the indicated times. RNA was collected and
qPCR was performed to determine the stability of mRNA. Data is of 3 experiments, mean± SEM.
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the Bone Marrow between the two genotypes (Fig. 8), this difference is because of both the
degradation of the mature miRNA and the lack of biogenesis of new miRNA [106].
4.3.2 p-p65 and A20 response in miR-17-92∆ BMDMs
By looking at phosphorylated p-65, a measure of NF-κB activation, in the immediate duration
after LPS challenge, there is a slight trend that the miR-17-92∆ BMDMs have a little less ac-
tivation than the miR-17-92fl littermate controls. This difference is however insignificant, and
furthermore there is no change in the protein levels of A20 following stimulation either. This in-
dicates that despite having lower miR-17-92 expression, any modulation of the immune system
is mild at best, and is not necessarily regulated by A20 in this model, but perhaps by something
else. To investigate this further, the scope of analysis must be widened.
4.3.3 Metabolic changes to stimuli of miR-17-92∆ BMDMs
In response to external stimuli, cells change their metabolic profile in order to better adapt to
the changing requirements of the situation. Immune cells, such as macrophages, are known to
adopt a more glycolytic setting upon activating of TLRs in order to quickly produce the energy
required for cellular proliferation and cytokine production [119]. To measure these changes,
BMDMs of miR-17-92∆and littermate controls were incubated with or without a low dose of LPS
for 8 hours and the metabolic reprogramming of the cells were measured using a Seahorse
assay. Interestingly, in basal conditions, the miR-17-92∆ BMDMs displayed slightly enhanced,
albeit insignificant ATP production, and non-mitochondrial respiration. There is however a sig-
nificant difference in the maximal respiration of the cells at basal conditions, however this differ-
ence is not as significant following LPS stimulation. This indicates that the miR-17-92∆ BMDMs
have a more oxidative phenotype, while interestingly also maintaining a greater glycolytic ca-
pacity to respond to stimuli. Furthermore, the presence of the miR-17-92 cluster may promote
Warburg metabolism, and its loss may inhibit it. While it is known that miR-17, 18a and 20a/b
target Hif-1α [120, 121, 122], and that miR-19 is upregulated in endothelial cells by Hif-1α activa-
tion [123], it makes sense that the reduction of these miRNA would results in a more oxidative
phosphorylation phenotype, given they also have roles in promoting cancer, which often has
Warburg metabolism. Furthermore, relieving miR-19 targeting of PTEN would also inhibit AKT-
mTOR signalling, reducing glycolysis within the cell [39].
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Figure 16:
Protein response of BMDMs to LPS stimulation. A. BMDMs were treated with LPS for 0, 5,
10, 15, 20 or 30 minutes before lysing and immunoblotted for p-p65. B. BMDMs were treated
with LPS for 0, 2, 4 or 6 hours with LPS lysed and immunoblotted for A20. C, D. Relative
intensity of p-p65 and A20 to β-actin respectively, represented as fold-change to miR-17-92fl
untreated. Blots are representative of and graphs are of 3 experiments, plotting mean± SEM,
analyzed with Mann-Whitney test, unpaired, nonparametric test
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Figure 17:
Metabolic changes in response to LPS stimuli. miR-17-92fl/fl and littermate miR-17-92∆
BMDMs were stimulated for 8hour with LPS (30ng/ml) and then were subjected to a sea-
horse assay. Analyzed with Mann-Whitney test, unpaired, nonparametric test. (*P<0.05 and
**P<0.01)
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4.4 iCLIP
In an attempt to discover what genes are directly regulated by the miR-17-92 cluster, BMDMs
from miR-17-92fl/fl and miR-17-92∆ mice were used to perform an iCLIP experiment. This pro-
cedure begins with the cross-linking of RNA with any protein within 1Å using UV-C (254 nm)
radiation. Following this, cells are lysed, the RNA is digested to manageable lengths, then a
protein of interest, in this case, AGO, is immunoprecipitated, the cross-linked RNA is extracted
and a library of cDNA is made. This resulting library can be sequenced to determine what and
relative quantities of genes are regulated at a specific moment by miRNA. Techniques like this
have been employed to determine the non-canonical binding of miR-155 and further our under-
standing of miRNA-mRNA interactions [124]. As it has been noted that iCLIP and other similar
techniques are technically demanding and challenging, with low yields, many recent advances
have made several steps more accessible, but much must still be done to improve the final
library yield and accuracy [125, 126].
RNA-protein interactions were fixed using UV-radiation to cross-link, then an AGO-IP was per-
formed to enrich the RNA-miRNA interacting population. Figure 18A and B show the successful
enrichment of AGO protein from lysates, with minimal contaminations. However the recovery
of useable cDNA for sequencing was poor. Even after 28 PCR cycles to amplify the libraries,
there was an uneven amount of cDNA in conditions from mice, as indicated in 18C.
4.5 miRNA expression in BMDMs
To investigate the global expression of miRNA and to observe wether the reduction of miR-17-
92 cluster had an effect on other miRNA, miRNA was measured using the Nanostring mouse
miRNA V1.5. Total RNA was purified from BMDMs of 3 littermate pairs and left untreated and
LPS stimulated. Figure 19 shows all miRNAs detected show largely the same expression, with
exception to the miRNA from the miR-17-92 cluster, which were significantly reduced. Impor-
tantly, the Nanostring data shows that the difference in miRNA expression is not as significant
as the previous qPCRs had indicated in figure 7. This opens the possibility that the LysM-Cre
driven deletion of the miR-17-92 cluster may not be as effective as previously thought.
4.6 Design of modular Nanostring Panel for macrophage inflammation
Nanostring technology is a technique of detecting individual mRNA molecules of a specific
species and counting them in an diagnostically accurate manner to interpret fine modulation
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Figure 18:
iCLIP results. Samples of iCLIP experiments, where the samples are separated by the animal
they came from M1-6. A. Coomassie stain of BIS-TRIS gels, indicating there was a reduction in
total protein following the IP. B. Western blot for AGO, indicating enrichment of protein following
IP. C. PCR amplification following 32 cycles of the different fractions of cDNA libraries. This
indicates low yield of cDNA species.
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Figure 19:
Expression of globalmiRNAdetermined by Nanostring. Most miRNA are expressed equally
between the WT and LysM-Cre BMDMs. miR-17-92 cluster member miRNAs show a clear
reduction, as indicated. Data is of 3x miR-17-92∆ mice and Littermate controls.
Fold Change Adjusted P Value Fold Change Adjusted P Value Fold Change Adjusted P Value Fold Change Adjusted P Value
mmu-miR-106a+mmu-miR-17 -1.2106 ****        < 0.0001 -1.0741 ****        < 0.0001 -0.2820 > 0.9999 -0.1455 > 0.9999
mmu-miR-19a -1.0193 ****        < 0.0001 -0.9050 ****        < 0.0001 -0.1699 > 0.9999 -0.0556 > 0.9999
mmu-miR-19b -0.9916 ****        < 0.0001 -0.8796 ****        < 0.0001 -0.3916 > 0.9999 -0.2796 > 0.9999
mmu-miR-20a+mmu-miR-20b -1.4061 ****        < 0.0001 -1.2123 ****        < 0.0001 -0.2115 > 0.9999 -0.0178 > 0.9999
mmu-miR-362-3p 0.1846 > 0.9999 0.2271   **             0.0048 -0.1061 0.8885 -0.0636 > 0.9999
mmu-miR-674 -0.9966 > 0.9999 -0.3154 > 0.9999 -0.9017     *            0.0244 -0.2205 0.5425
mmu-miR-2135 0.1199 > 0.9999 0.5712 > 0.9999 0.3279   ***           0.0002 0.7792 ****        < 0.0001
mmu-miR-1224 -0.1679 > 0.9999 0.2134 > 0.9999 0.3080 > 0.9999 0.6892    *             0.0157
mmu-miR-199a-3p 0.1558 0.0535 -0.0426 > 0.9999 -0.2235 > 0.9999 -0.4219 > 0.9999
mmu-miR-155 0.0443 > 0.9999 0.2202 > 0.9999 0.4187 > 0.9999 0.5946 0.0641
mmu-miR-146a 0.7318 > 0.9999 0.2190 > 0.9999 0.9494 > 0.9999 0.4366 > 0.9999
miR-17-92 :UT vs WT:UT miR-17-92 :LPS vs WT:LPS WT:LPS vs WT:UT miR-17-92 :LPS vs miR-17-92 :UT
Table 7:
miRNA expression assessed by Nanostring of miR-17-92∆ BMDMS. miRNA that are sig-
nificantly changed following LPS stimulation between WT and LysM-Cre BMDMs. Same pairs
of mice as in Figure 19. 2-way ANOVA with Tukey Multiple comparisons test was performed,
*p<0.032 **p<0.0021 ***p<0.002 ****p<0.001.
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of gene expression, unmodulated by amplification biases. The challenge put to me was to de-
sign a panel of genes that can be used by many projects in the institute, and easily changed
depending on the needs of the investigators. As the vast majority of projects use macrophages,
dendritic cells and neutrophils, these were the core cell types considered when designing this
panel. Secondly, as most individuals were analyzing the modulation of secreted cytokines and
other immune activation markers, these genes were given priority for inclusion.
To achieve this, the Elements chemistry was chosen, allowing the analysis of up to 192 genes
per sample, across 12 samples to be completed in 2 days. By dividing the genes into “bins” of
24 genes, 8 panels can be multiplexed to assess different clusters of genes depending on their
function.
Using this project design, researchers can quickly adapt the nanostring panel to their require-
ments, and investigate required bins only. Furthermore, when a new set of genes is required,
only the bins of tags must be ordered, instead of a whole new kit. Several variants of this panel
has been used to investigate the patient samples, the effect of small molecules on human mono-
cytes, the effect of infarction on mouse heart derived macrophages, DCs and myocardyocytes.
To investigate the effect of LPS on transcription in miR-17-92∆ BMDMs, the panel chosen was
with TypeI IFN and metabolism and stress, based upon previous results that metabolic pro-
cesses may be influenced (Figure 17). BMDMs from either miR-17-92∆ mice, or littermate WT
controls showed almost identical responses, as outlined in figure 21. Previous studies have
found that while miRNA do ultimately regulate protein expression, measurements of RNA is
still an effective method of detecting miRNA activity [127, 128, 129, 38]. While the Nanostring
is measuring a limited selection of genes, the panel was designed to specifically measure the
innate response, and as such has shown that there is nearly no difference between the miR-
17-92∆BMDMs transcriptional response compared to the WT littermate controls. This speaks
volumes not only of the accuracy of the nanostring, but how similar the two genotypes are to
each other, and how little the miR-17-92 cluster has an effect on in macrophages. From this, it
is concluded that in vitro prepared BMDMs from miR-17-92∆ mice are almost indistinguishable
from their WT littermate controls when examining gene expression, indicating that reduction
of the miR-17-92 cluster does not have an effect on LPS-induced transcription of genes, in
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Figure 20:
Nanostring Elements Modular design theory. A. Diagram showing how the Nanostring
nCounter® Elements™ Reagents works. Diagram adapted from the nCounter® Elements™ XT
Reagents User Manual, available online. B. Bins of 24 genes with a central theme (annotated
with letters) can be mixed together is a specific order to create a 192 gene custom Nanostring
assay, specifically designed to analyze macrophages, neutrophils and dendritic cells. If an-
other panel of genes is preferred, it can be replaced with a replacement panel (annotated with
number), designed to measure a separate theme of genes.
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Figure 21:
Nanostring analysis of gene expression of miR-17-92fl/fl - LysMCre BMDMs. Volcano
plots of fold gene expression and significance between miR-17-92fl/fl BMDMs and miR-17-92fl/fl
LysmCre BMDMs analysed with the modular Nanostring Elements containing Type I IFN, and
Metabolism and Stress panels. A. Effect of LPS stimulation on miR-17-92fl/fl (WT) BMDMs. B.
Effect of LPS stimulation on miR-17-92∆ BMDMs. C. Comparison of miR-17-92∆ and littermate
miR-17-92fl/fl BMDMs stimulated with LPS. D. Comparison of miR-17-92∆ and littermate miR-
17-92fl/fl BMDMs at basal gene expression (unstimulated). WT=8 miR-17-92∆=10 p-Values are
Bonferroni multiple comparisons corrected.
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agreement with findings from the 24 hour LPS stimulation (Fig. 14).
4.7 In Vivo response to LPS of miR-17-92∆macrophages.
4.7.1 Selection of cells from in vivo experiments.
When performing the in vivo experiments, it was important to use magnetic beads to select
a specific population of cells that expressed the modulated miR-17-92 cluster, and not take a
mixed population. To test this, WT mice were sacrificed for their spleen, blood, and peritoneal
lavage, and then each subjected to either F4/80 or CD11b magnetic MACS selection. Following
selection, the cells were stained for either F4/80 or CD11b and analysed by FACS. As shown in
figure 22, enrichment with Cd11b was comparable to F4/80 enrichment of the peritoneal lavage
cells. However Cd11b magnetic selection was superior when collecting CD11b, F4/80 double
positive cells, and even F4/80+ CD11b- cells. For this reason, CD11b magnetic selection was
chosen to collect cells ex vivo from mouse tissues.
4.7.2 In vivo miRNA response to LPS challenge.
To investigate the effect of the miR-17-92 cluster in an in vivo setting, miR-17-92∆mice and litter-
mate controls were injected with either PBS or LPS intraperitoneally, and monitored for 6 hours,
to mimic an acute inflammatory response to infection. Mice were sacrificed and their spleen,
blood and peritoneal lavage were taken, and cells were magnetically selected for CD11b selec-
tion. As the peritoneal cells had the major difference in miR-17-92 expression, these were of
most interest (see figure 10). Using the Nanostring, global miRNA expression was measured
from either PBS or LPS injection of 24 mice, (2 were removed due to poor performance of the
assay). Figure 23 indicates that there was a lot of variation in the Nanostring miRNA datasets.
Much of the variation however can be explained by several non-experimental variables, includ-
ing the age and gender of the animals. The largest variable however is the effect came from the
cage that the animals were housed in prior to the experiment taking place. Figure 23C shows
that when correcting for the cage the animal is from, error within the dataset is reduced. It must
also be noted that the cage the mice were housed in also determines the animal’s age and
gender, as mice of the same gender and litter are housed together, regardless of genotype.
However, the contribution of age and gender alone are quite small compared to the effect of the
cage (Figure 23B). The PCAs shown in Figure 24 show that with cage correction, the datasets
have not been overcorrected. Furthermore, each of the conditions clusters separately, indicat-
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Figure 22:
Comparison of CD11b and F4/80 selection of cells from Spleen, Peritoneum and whole
blood. FACS enrichment of CD11b and F4/80 cells. The spleen, blood and peritoneal lavage
were prepared and then magnetically sorted for F4/80 or CD11b expressing cells. After selec-
tion, cells were stained for F4/80 and Cd11b and FACS analysis was performed. Values here
are % number of cells in a sample. n=6 Mean with SEM.
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ing that there are subtle differences between them. Interestingly, cage effects on mice have
been previously reported,
miRNA expression and fold changes from peritoneal CD11b+ from 4.7.2 are represented here
as volcano plots in Fig. 27. The vast majority of miRNA are unchanged either between the two
genotypes, or following challenge, as indicated here. After correcting for changes due to the
cages, the miRNA expression was graphed as mean with SEM and found 2-way ANOVA was
performed, with Tukey’s multiple comparisons test. Unsurprisingly, most of the miRNA showed
no to little difference between the conditions, or showed a small change between stimulated
and non-stimulated conditions. Fig. 25 shows miRNA that have a significant difference between
stimulated and unstimulated conditions, but no significant differences between the WT and miR-
17-92∆ littermates. 23 miRNA showed a significant change in the miR-17-92∆ mice alone, and
only two showed significance on in the WT, and 6 showed a significant change within each
genotype. This is a further indication that there is global dysregulation of miRNA in the miR-17-
92∆.
To investigate which pathways may be regulated by the significantly changed miRNA from the
peritoneal cells, the predicted targets were collated from Targetscan [105] and then Pathway
enrichment was performed using Partek. Table 8 outlines the results of this analysis. While un-
surprisingly, most of the top predicted pathways that are likely to be regulated by the modulated
miRNA are cancer and pluripotency related, the first immune-related pathway prediction is in
position 14, the TGF-β pathway. Furthermore, NF-κB and TLR pathways do not appear until
near the end of the list, with extremely poor enrichment scores, indicating that the vast majority
of predicted targets that are likely to be modified in the cells are not involved in immune functions
at all. This is further backed up by the lack of difference when immunologically challenging the
cells.
An interesting explanation for the many changes in miRNA expression is the loss of miR-20a,
may free up the component required for it, and many other miRNA maturation, Khsrp. This is
further investigated in Supplementary section 7.3, on page 84.
4.7.3 In vivo Cytokine response to LPS challenge.
Further investigation of the peritoneal lavage and sera of mice challenged with LPS revealed that
there was no significant differences in any cytokines produced by the miR-17-92∆. In the sera
of the mice, where no observable difference in miR-17-92 expression was observed (figure 10),
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Figure 23:
Quality and variance analysis of miRNA detected by Nanostring from peritoneal cells.
Detection of miRNA levels using nanostring of CD11b+ peritoneal cells from PBS or LPS in-
jected animals. A. Average counts of all miRNAs are plotted, and threshold where miRNAs
are detected in at least 50% of samples is plotted on Y-axis. X-axis shows the cutoff, with 336
miRNAs detected, and 275 miRNAs considered undetected. Sources of variation from in vivo
peritoneal miRNA Nanostring. B. The total sources of variation considering all factors. Cage
and gender are co-dependant. C. Error in dataset before Cage correction. D. Error in dataset
following Cage correction.
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Table 8:
Partek Pathway Enrichment of predicted targets. Predicted targets calculated by Targetscan
of miRNA that were found to be significantly changed in peritoneal mø between miR-17-92fl/fl
and miR-17-92∆ mice, injected with LPS. Not all predictions are tabulated, sets of missing pre-
dictions are depicted as gaps in the table. Of 303 ranked pathways, NF-κB and related pathways
appear at the bottom of the list, with almost no significance.
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Figure 24:
Effect of cage correction on miRNA expression PCA. Each dot represents a single animal.
A. PCA of dataset before Cage correction. B. PCA of dataset following Cage correction.
it was reasoned that there would be little difference in cytokine response to IP LPS challenge.
Indeed, there was no observable differences between miR-17-92∆and WT littermates, except
a slightly elevated Cxcl1. In the peritoneal lavage, where there was a large difference in miR-
17-92 expression however, there is also no observable differences, mirroring the in vitro results
(figure 13). IL-10 and IL-13 appear slightly reduced, while IL-23 is mildly enhanced, however
none of these observations are significant. IL-13 however is secreted by Th2, NKT and Mast
cells among others [130], but not macrophages. It is interesting to note that macrophages are
required to maintain IL-13 signalling from Th2 cells in vitro [131], and that the miR-17-92 cluster
has already been shown to enhance Th2-driven responses [42]. These raise the possibility that
the miR-17-92 cluster does affect macrophage interaction with T-cells and play a role in type 2
cytokine responses.
Of note, Il-23 is mildly enhanced in the miR-17-92∆ mice compared to the WT littermates when
looking in the peritoneal lavage, while IL-10 is slightly reduced. This has been previously ob-
served that IL-10 is critical in regulating IL-23 release from macrophages [132].
These results mimic those of the in vitro, namely that modulating the miR-17-92 cluster in
macrophages has no effect on cytokine release when stimulated with LPS in vivo. Further
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Figure 25:
Significantly differently expressed miRNA within miR-17-92∆ or WT peritoneal cells stim-
ulation. miRNA expression following 2-way ANOVA with Tukey multiple comparisons of differ-
ences between miR-17-92fl/fl and miR-17-92fl/fl - LysM-Cre -/+ peritoneal CD11b+ lavage cells
following PBS or LPS injection. miRNA shown here have no significant difference between the
miR-17-92∆ and WT groups, but do show a change within their respective conditions. *p<0.032
**p<0.0021 ***p<0.002 ****p<0.001
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Figure 26:
Significantly differently expressed miRNA between miR-17-92∆ and WT littermate peri-
toneal cells. miRNA expression following 2-way ANOVA with Tukey multiple comparisons
test of differences between WT and miR-17-92∆ peritoneal CD11b+ lavage cells following PBS
or LPS injection. Data is shown as Nanostring Digital counts on the y-axis. miRNA shown
here have a significant difference between the miR-17-92∆ and WT mice. *p<0.032 **p<0.0021
***p<0.002 ****p<0.001
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Figure 27:
Volcano plots of miRNA peritoneal expression. miRNA detected from peritoneal CD11b+
cells using the Nanostring. A: The effect of LPS on WT peritoneal cells. B. The effect of LPS
on miR-17-92∆ peritoneal cells. C. Comparison of PBS treated miR-17-92∆ and WT littermate
mice. D. Comparison of LPS treated miR-17-92∆ and WT littermate mice. All data is FDR
step-up corrected. X-axis show fold change and Y-axis show p-value.
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work should be done to verify if the regulation of the cluster does effect macrophage commu-
nication and interaction with other cells, such as Th2 cells, and modulate their own responses.
As a test to see if there were any other measurable differences between the WT and miR-
17-92∆mice, the peritoneal CD11b+ cells from the LPS and PBS injected mice were analysed
using 3’ sequencing. 28768 genes in total were identified, with 1280 and 1097 genes up- and
down-regulated in the miR-17-92∆mice, and 1073 and 869 genes in the WT mice respectively,
using FDR step-up correction for multiple comparisons. When comparing the WT and miR-
17-92∆samples directly, there was no difference observed when comparing the PBS injected
mice. However, two genes were significantly different between the LPS treated samples, Lyz1,
and Gm20390 (Fig. 30 D). Neither of these genes harbor MREs for any of the miR-17-92
miRNA, indicating that the differences observed are not due to direct miRNA interaction with
the transcripts, but are caused by some other means. GM20390 is a transcript caused by the
fusion of the Nme2 and Nme1 genes. As this has been identified by 3’ sequencing only, it is
possible, yet not necessarily the case, that the gene actually being identified is Nme2, as a
BLAST confirmed that there is a striking similarity in the 3’ end of Nme2 and GM20390.
Interestingly, there are also differences, yet insignificant, in Lyz2 and Mir17HG expression. It is
likely that the miR-17-92∆are trying to express more Mir17HG, in response to lowered levels of
mature miR-17-92 miRNA. This mirrors what was seen when examining the expression of the
Mir17HG by qPCR (Fig. 14).
72
PB
S
LP
S
0
200
400
600
pg
/m
l
G-CSF
PB
S
LP
S
0
1000
2000
3000
4000
5000
IL6
pg
/m
l
PB
S
LP
S
0
2
4
6
8
10
IL12p70
pg
/m
l
PB
S
LP
S
0
10
20
30
40
MIP1 alpha
pg
/m
l
PB
S
LP
S
0
100
200
300
IL19
pg
/m
l
PB
S
LP
S
0
100
200
300
400
IL10
pg
/m
l
PB
S
LP
S
0
500
1000
1500
IL22
pg
/m
l
PB
S
LP
S
0
2
4
6
GM-CSF
pg
/m
l
PB
S
LP
S
0
100
200
300
400
MCP3
pg
/m
l
PB
S
LP
S
0
50
100
150
IL28
pg
/m
l
PB
S
LP
S
0
10
20
30
40
LIF
pg
/m
l
PB
S
LP
S
0
10
20
30
40
50
IL9
pg
/m
l
PB
S
LP
S
0
500
1000
1500
2000
2500
GRO-alpha (Cxcl1)
pg
/m
l
PB
S
LP
S
0
1000
2000
3000
4000
5000
MCP1
pg
/m
l
PB
S
LP
S
0
50
100
150
200
MIP1 beta
pg
/m
l
PB
S
LP
S
0.0
0.5
1.0
1.5
2.0
2.5
M-CSF
pg
/m
l
PB
S
LP
S
0
20
40
60
80
100
IL13
pg
/m
l
PB
S
LP
S
0
200
400
600
RANTES
pg
/m
l
PB
S
LP
S
0
50
100
150
IL17a
pg
/m
l
PB
S
LP
S
0
10
20
30
40
IL17f
pg
/m
l
PB
S
LP
S
0
100
200
300
400
IP-10
pg
/m
l
PB
S
LP
S
0
10
20
30
40
IL23
pg
/m
l
PB
S
LP
S
0
20
40
60
80
TNFa
pg
/m
l
PB
S
LP
S
0
50
100
150
200
MIP2
pg
/m
l
Sera Cytokines
WT
KO
Figure 28:
In vivo cytokine detection from sera. Mice injected IP with either LPS or PBS were sacrificed
and a small amount of blood was collected with EDTA. The sera from this was diluted 1:3 and
measured using the Magpix multiplex custom assay. No statistical significance is observed
when performing a 2 way ANOVA, with Tukey’s multiple comparison test.
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Figure 29:
In vivo cytokine detection from peritoneal lavages. Mice injected IP with either LPS or PBS
were sacrificed and a peritoneal lavage was collected. This was diluted 1:3 and measured using
the Magpix multiplex custom assay. No statistical significance is observed when performing a
2 way ANOVA, with Tukey’s multiple comparison test.
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Figure 30:
3’-seq from CD11b+ peritoneal cells. Volcano plots of RNA-sequencing data from peritoneal
cells in vivo experiment, using FDR corrected p-values. Comparison of A. LPS and PBS injected
WT mice, B. LPS and PBS injected miR-17-92∆ mice, C. PBS injected WT and miR-17-92∆ D.
LPS injected WT and miR-17-92∆. Down-regulated genes are in green, and up-regulated genes
are in red.
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5 Discussion
This study focused on the role of the complete miR-17-92 cluster and its potential role regulating
the innate immune response in macrophages. This is based on the work indicating that miR-
19b targets Tnfaip3, Rnf11, Kdm2a and Zbt16 [40]. This coordinated suppression of genes with
similar roles meant that miR-19b could deftly promote NF-κB activity. These results relied on
the use of AMOs, which are more than capable of sufficiently and specifically inhibiting miRNA
activity, they are not physiologically representative of a diseased state where the miRNA are
modified in an organism. To further this research, the miR-17-92∆ mouse was generated to
identify if perturbations of the miR-17-92 cluster as a whole would have effects on the innate
immune system, specifically through NF-κB, in macrophages. The results from the experiments
using this animal model however suggest that even though minor perturbations of miRNA are
known to often cause disease, reduction of the miR-17-92 cluster does not have a huge effect
in macrophages specifically.
miR-19a was recently discovered to be significantly upregulated following Tnfα stimulation of
macrophage and dendritic cells from the colon in mice [133]. Its expression however is mostly
associated with tumour tissues, not with normal tissues [133]. Furthermore, the same paper
describes increased p-p65 and COX-2 following miR-19a mimic injection, and increased levels
of both mRNA and protein of Tnfα, Il-1β, Il-6 and Il-17. However, in this study the epxression
of this cluster decreased following stimulation, as observed in both mature miRNA (Nanostring,
Fig. 26) and prim-miRNA forms(qPCR, Fig. 14). This highlights the contrasting nature of
macrophages from different tissues, and the likelihood that regulation of powerful modulators,
such as miRNAs is likely significantly different depending on the location and context of cells.
To further this point, it has been published that the miR-17-92 cluster must be down-regulated
in macrophages for normal function, whereas enforced expressing inhibited macrophage mat-
uration [115]. In a separate study, miR-17 and -20a down-regulation was found to be critical
in monocytic cells because of a negative feedback loop, as the miR-17 family of miRNA re-
press the expression of RUNX1 [134]. This critical transcription factor is important for the mat-
uration of haemopoetic progenitor cells to myeloid cells, and enhances the expression of the
M-CSFR. These discoveries indicate that a relaxed expression of miR-17 is likely critical for
normal macrophage function. Interestingly though, in the data here, expression of the Mir17HG
is decreased following LPS stimulation. It is possible that this is a reaction to the regulation
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of NF-κB signalling by the cluster. It is also possible that this lull in transcription is due to the
overwhelming transcription of other genes in response to the LPS challenge.
However, it must be noted that the expression of the cluster in macrophages is still well-represented
in the landscape of all miRNAs when following normal lab protocols to produce either L929, or
M-CSF derived BMDMs. Indeed, while the expression is slightly reduced from total Bone Mar-
row (Fig. 8) in WT BMDMs, given there was no appreciable difference between miR-17-92∆
and WT cells when it came to macrophage cytokine production. It is conceivable that loss of
the miR-17-92 cluster has counteracting positive and negative effects, both inhibiting NF-κB ac-
tivation and promoting macrophage maturation, effectively having opposing effects that results
in a net lack of change.
Furthermore, other groups have claimed that the mir-17-92 cluster still has roles in macrophages,
such as regulating autophagy proteins in cystic fibrosis [135]. Using antagomiRs, it was shown
that miR-17 and miR-20a target both Atg7 and Atg16l1, while mice that were injected intratra-
cheally with antagomiRs had enhanced expression of these genes in their macrophages. These
mice were also able to clear Burkholderia cenocepacia infection in the lungs better, presumably
though autophagy-related mechanisms. An issue with this study is the reliance on huge doses
of antagomiRs, resulting in non-physiological responses, especially as the little had been shown
if there were any off-target effects of using such therapies [136].
A confounding observation is this study is that there is a reduction of Tnfα released from BMDMs
infected with Cre-expressing virus, but no observed difference using the miR-17-92∆ BMDMs
(Fig. 5 and Fig. 13). It is possible that because the BMDMs for the viral experiments were
infected 3 days after beginning of culture, by day 7, when the cells were used, we could ob-
serve a difference in cytokine release. The miR-17-92∆ BMDMs should have Cre recombinase
expressed from day 1 (Fig. 8), meaning the cells have had a reduced miR-17-92 expression
for a longer time. There could conceivably be a compensatory mechanism that is unobserved
in the cells infected with the Cre- virus that is confounding the results. Furthermore, Cre toxicity
may also have a role to play, although was not further investigated in this study.
There are many complications when it comes to miRNA research, but it seems that there are
also many redundancies in miRNA expression too that are, as of yet, not well understood.
In the CD11b+ cells from the peritoneum of miR-17-92∆ mice , levels of miR-125 and miR-
221 are elevated, and both are also published to target A20 (Fig. 26) [95, 137]. While it is
unclear wether the loss of the miR-17-92 cluster directly deregulated the expression of these
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miRNAs, or if the expression of other transcription factors has been affected, it does indicate
that the modulating the miR-17-92 cluster does affect the expression of others. This shift in the
expression of so many miRNA, such as miR-125, which have competing effects of the miR-
17-92 cluster, would allow stabilising the expression of genes. This might alleviate the effects
initially hypothesized to be observed. Significant care must be taken when claiming that a
miRNA regulates a certain gene, as physiological contexts may allow for these redundancies
to be tolerated. This represents another facet where the miR-17-92 cluster may have opposing
effects, especially when examining macrophage function [115, 134]. As an example, while
miR-19 has been shown to be a positive regulator of NF-κB signaling [40], miR-20 is a negative
regulator [12]. Strong modulation of a single miRNA or group of miRNA may not translate to a
physiological state.
One critical problem with the model generated in this study is the deletion of the miR-17-92 clus-
ter was incomplete in all tissues tested. While the deletion is most prominent in both BMDMs
and peritoneal cells, there is no observable reduction in miRNA in either the blood or splenic
CD11b+ fraction (Fig. 10). However, the original paper that describes the invention of the LysM-
Cre mouse indicates that there are between 83-90% deletion of the target gene observed in the
splenic fraction and peritoneal fractions, and attributes this to the residual macrophages within
that are highly differentiated [100]. It is intriguing that there is poor deletion observed in the
splenic and peripheral blood compartments, as both these populations of cells are usually old
enough to observe cre-driven deletion. This raises several possibilities; the miR-17-92 clus-
ter, or miRNAs within, are critical for the survival of circulating macrophages, the cell turnover
in these compartments is too quick to observe effects, or that there is not enough LysM-Cre
induction, resulting in a lack of deletion [116]. However, as previously noted, deletion of the
cluster is not compatible with life, and generating miR-17-92KO lines using cre-recombinase
does have difficulties regarding cell proliferation [37, 42]. It is also perhaps not the fault of the
LysM-Cre model, as it has been used successfully for other miRNA research, where the cells
survived [66]. In future studies, an inclusion of a LysM-Cre mouse without a gene-flox would be
advisable, given that there are reports that intracellular DNA fragments from Cre-recombinase
activity can activate STING [138]. While there are no aberrant STING or interferon responses
observed in this study, it may also explain the significance of the difference in Lyz1 expression
in the sequencing data (Fig. 30).
Gut microbiota explains many susceptibilities to diseases [139]. Much variation due to gut micro-
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biota can be explained due to cage differences where the mice are housed [140]. Furthermore,
as mice that are littermates are stored in the same cage together, depending on their sex, it
makes it ideal in this study to examine littermate control mice while investigating miR-17-92fl/fl
mice. Of interest, no papers were found outlining the effect of cage differences and drift on
the expression of miRNA, and in peritoneal cells. While it is quite likely that the differences in
miRNA expression or just artifacts of the parental genetic background, if this is the case it would
really speak volumes to how small the changes are in miRNA expression in direct response to
the loss of the miR-17-92 cluster.
One possibility that must be entertained is that by perturbing this cluster alone, other miRNA may
fill in the void left. miRNA regulate the expression of protein noise by decreasing the noise of
lowly expressed proteins, however they increase the noise of highly expressed genes [141]. As
indicated by the Nanostring of total miRNA from the peritoneal cells of mice, the global miRNA
noise is enhanced following the deletion of the miR-17-92 cluster. It is possible that then genes
such as A20 have more noise at lower expression levels now that the regulating miRNA are
removed, however when stimulated, their noise levels are left unchecked, allowing for more
variability. This variability is unpredictable, and thus, in a mixed population of cells, any effect
is lost due to noise.
However, other evidence is more direct, as miR-125a and b are both inhibitors of A20 [95].
Interestingly, both of these miRNA are expressed higher in the KO cells than the WT cells when
looking at the nanostring data of the peritoneal cells from the in vivo. This may then explain
how there is no observable effect on A20 in the KO cells, Furthermore, there may be other
more complicated means of the cell regulating dysregulation of the miR-17-92 cluster that have
not be appreciated yet.
Other groups have also attributed miR-19 as a major component of inflammation. Injection
of miR-19a mimics into the peritoneum of mice enhanced the formation of colon cancers in a
DSS + azoxymethoane driven colitis-associated colon cancer model. The study also shows
enhanced sera presence of several cytokines including Tnfα, IL-6 and Il-1β, to name a few. The
paper further attributes this progression in cancer to miR-19a targeting Tnfaip3 in tumours. Of
critical note though, this model is flawed, as injection of mimics enhances the expression many
thousand-fold, and brings some questions of physiological relevance. There is also no mention
of how the mimics are taken up by cells, only the enhanced expression in tumours of ~1.7 fold
[133]. The model that is used here in this study represents a more physiological representation
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of miRNA dysregulation.
The delicate interplay between miRNAs and targets following stimulation was eloquently exam-
ined by Mann et al recently, where miR-155 was induced rapidly following stimulation and NF-κB
activation. miR-155 inhibited SOCS1 and SHIP1, allowing for a robust and full response. This
ensured a later induction and accumulation of miR-146a, which could inhibit IRAK1 and TRAF6,
leading to a smooth but quick decrease in inflammatory responses and miR-155 expression,
which release SOCS1 and SHIP1 expression once more, further accelerating the shutdown of
inflammatory response. This study also uses the LysM-Cre model for myeloid specific deletion
of miRNA, indicating that this model is a viable model for miRNA research [66].
Many previous studies have found that miRNA interaction with mRNA leads to reductions in
mRNA that are also correlated with changes in protein levels [127, 128, 129]. However, a
more recent paper has indicated that the miR-17-92 cluster does not necessarily regulate gene
expression at the transcriptional level, but has a greater observable effect at the protein level
[142]. There may be more merit in trying to observe effects on direct targets by means other
than qPCR then. While this may be the case, there however is still no change of protein as
determined by western blot, nor cytokine release, when investigating the miR-17-92∆ cells. This
however does not exclude the possibility of transcriptional differences that are a result of protein
dysregulation in genes such as A20.
Further complicating the matter, A20 expression is regulated by NF-κB, which in turn down-
regulates its own expression. By disrupting the miR-17-92, and hopefully stabilising A20 ex-
pression, there would be reduced NF-κB activity, but conversely, lower A20 expression too. It
would therefore be difficult t fully characterise the anti-inflammatory role of the miR-17-92 clus-
ter through measurements of A20, and may explain why there is no observable change in A20
expression by protein analysis.
Moreover, there are reports that indicate changes to miRNA expression does not correlate to
an appreciation in their function [143], and that only highly expressed miRNAs tend to show
significant target repression [144]. This is a potential reason why there is no observable effect
of reducing the miR-17-92 cluster in macrophages in this study; that the expression is too low in
the first place. Furthermore, by altering the expression, there is potentially not a distinct change
in their loading, and so the cell continues to behave as normal. This may be entirely why there
is little literature on the role of the miR-17-92 cluster in macrophages, but why there is a relative
glut in research using B-cells.
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This lends credence to the use of CLIP experiments to investigate the effect of the miR-17-
92 cluster and targeting direct mRNA targets. While the experiments performed for this thesis
were not a complete success, previous efforts in PAR-CLIP of EBV-infected Human B-cells
had promising results [145]. While the data was not acquired from true miR-17-92 overex-
pressing/knockout cells, they are still useful to identify bone fide miR-17-92 targets. Among the
targets identified included RNF11, TNFAIP3, SOCS1 and CYLD, and other metabolic genes in-
cluding HIF1α. This still lends hope to the fact that the miR-17-92 cluster does regulate negative
regulators of NF-κB, however, as this data was collected in B-cells, this is not representative of
the biology in macrophages, indicating that they must still be investigated further.
An area that has not been explored in this current study is the possibility of long non-coding
RNA (lncRNA) regulation of the miR-17-92 cluster. It has been hypothesized that lncRNA may
regulate miRNA expression via binding and sequestering them away from functional targets
[146]. There is huge diversity of lncRNA in its many forms available and expressed from the
genome [147, 148, 149], and lncRNA are known to have roles in the progression of innate
immune diseases and cell types [150]. Furthermore, miR-19 has been posited to be regulated
by HOTAIR, a more well-known lncRNA, where its expression was inversely proportional to
HOTAIR expression, which alleviated the regulation of PTEN [151]. HOTAIR is considered
pro-inflammatory, and while most of its effects are as a scaffold molecule (reviewed in [152]),
it is overexposed in PBMCs from Arthritis patients [150], it enhances CCL2 expression [153]
and also TNFα due to enhanced expression in sepsis conditions [154]. Furthermore, more
recently, another lncRNA, circ-ITCH has been described, and credited in regulating miR-17
[155]. It would be interesting to investigate if changes of the miR-17-92 cluster also change the
expression of other lncRNAs.
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6 Conclusion
Previous work has established members of this cluster as pro-inflammatory, regulating T cell, B
cell and epithelial cell driven inflammation. This study tried to investigate wether the miR-17-92
cluster has an appreciable effect on the function of macrophages in the context of inflamma-
tory diseases. While the miR-17-92 cluster was successfully reduced in macrophages in vivo
and ex vivo by greater than 50%, which is reasonable to assume in a physiological context,
surprisingly there was no appreciable change to the function and response of macrophages to
immune stimuli. It is likely that the miR-17-92 cluster affects other pathways and genes more
than the hypothesized targets, such as Tnfaip3. This is because miRNAs role in cells is context
dependent, and the abundance of other, yet unappreciated targets, is greater.
Furthermore, stimulation of the macrophage reveals there is a small difference in metabolic
processes, however there is no appreciable difference when examining cytokine release and
gene expression, when analysed using a custom modular Nanostring kit. When examining the
function of macrophages in vivo, it appears that there are changes to the expression of other
miRNA, yet this does not translate to changes in either cytokine release nor gene expression.
Together, these results indicate that while the miR-17-92 cluster does play a role in inflammatory
diseases in other cells types, it likely does not contribute to the primary cytokine response from
macrophages. This highlights firstly, the different roles that miRNA play in different tissues and
cell types, and seondly, that in vitro studies do not always translate to in vivo physiological
results. It is possible that using other methods to dampen the effect of the miR-17-92 cluster
may yield different results, however physiological relevance is brought into question then.
This study is not exhaustive, and there is some evidence that indicates there are potentially
competing effects of the miR-17-92 cluster in macrophages. Further investigation into the bind-
ing of miR-17-92 cluster members could potentially reveal as-yet undiscovered redundancy
mechanisms in macrophages. Furthermore, inhibition and analysis of individual miRNA from
the miR-17-92 cluster may yield interesting results that may not be compounded by reducing
expression of the entire cluster of miRNA. These experiments could investigate other roles for
these miRNAs in macrophages, including inflammation, activating and facilitating responses of
other cells, and initiating Type 2 response from T cells.
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7 Supplementary Information
7.1 Publications of miR-17-92 cluster members regulating genes.
While miRNA analysis using algorithms to predict binding works reasonably well, it does not
always translate to biological action. Following from the information in Fig. 6, supplementary
table 6 provides an up-to-date list of research articles that show interaction of members of
the miR-17-92 cluster and genes involved in the regulation of innate immune signalling and
responses.
Gene miRNA family Publications
Tnfaip3 miR-19, miR-18 [40, 42, 45]
Rnf11 miR-19 [40, 97]
Fbxl11 miR-19 [40]
Cyld miR-19 [98]
Atg16l1 miR-17 [156]
Itch miR-17 [157]
Ikzf1 miR-92 [158, 159]
Ikzf4 miR-17 [160]
Socs1 miR-19 [161, 42]
Socs3 miR-19 [96, 162]
Socs6 miR-17 [163]
Hif1a miR-17, miR-18 [164, 122, 121]
Pten miR-19, miR-17, miR-92 [39, 158]
Fxr1 miR-92 [165]
S1pr1 miR-17, miR-19, miR-92 [159]
Bcl2l11 miR-19, miR-17, miR-92 [166, 37, 158]
Table 9:
List of publications that confirmed miR-17-92 regulation of negative regulators of NFkB.
7.2 2’OMe AMO sequence specific binding of TLR7
Figure 31 was generated from experiments performed and published in the paper “Sequence-
dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors” [136]. By
transfecting AMOs into BMDMs using DOTAP, a common method to deliver small RNA molecules,
and subsequently stimulate TLR7, there was a reduction in TNFa release by inhibiting miR-19a
and interestingly with miR-92a as well. However, the use of a 2′OMe control non-targeting AMO
reduced the release of mTNFa further, when compared with a non-2′OMe control RNA. Impor-
tantly, when using miR-17-92∆ BMDMs, with reduced miR-17-92 expression, this inhibitory ef-
fect is still observed, indicating that the observed phenomenon is not dependent on the AMOs
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Figure 31:
Zen AMO off target effects. BMDMs of miR-17-92∆ mice or littermate controls were isolated
and transfected with 40 nM of the indicated 2′OMe AMO or non-2′OMe control RNA (RD) endo-
somally using DOTAP, then stimulated with 180 nM of the ssRNA B-406AS-1. After overnight
stimulation, the supernatants were tested for mTNFa release. Data is of 3 independent experi-
ments, and normalised to RD. Two-way ANOVA was performed comparing the RD control, with
Dunnett’s multiple comparisons test, and an alpha set to 0.05.
ability to target and sequester miRNA, but rather inhibit TLR7 signalling itself.
From this, the authors then began to investigate how 2′OMe AMOs can bind, but not acti-
vate TLR7 in a sequence-dependent manner. This provides a another complication to AMO-
dependent miRNA research that users must be considerate of.
7.3 Khsrp regulation of miRNA modulated by the aberrant expression of miR-
20a
KH-type splicing regulatory protein (Khsrp) interacts with and regulated many mRNA expression
in cells, and in 2009 was discovered to also regulate and promote the expression of many
miRNAs too [34]. By knocking down Khsrp, the expression of several miRNA was significantly
reduced (between 1.2 and 1.5 fold). Among these miRNA is miR-20, the most highly expressed
of the miR-17-92 cluster in macrophages. Interestingly, even though its expression is very
high, the accessibility of Khsrp to its binding site is very difficult in the folding of the pri-miR-
17-92 molecule. By taking the miRNAs that were reduced in Khsrp knock-down conditions of
THP-1 cells, and examining their expression from peritoneal CD11b+ cells extracted from PBS
injected mice, many of these miRNA are expressed at a slightly higher level with reduced miR-
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17-92 expression. This could indicate that by reducing Khsrp-processable miR-20a, it allows
for Khsrp to bind and mature many other miRNA.
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Figure 32:
Fold change of Khsrp regulated miRNA. Expression of miRNA from PBS injected mice that
are known to be regulated by Khsrp. Expression is represented as fold change over the WT
expression.
7.4 QAQC of 3’-sequencing of RNA from CD11b+ peritoneal cells.
To compliment the sequencing performed using the in vivo samples, Supplemental figure 33
shows that the samples performed the same an were all high quality, however when examin-
ing the differences, there was little to discern. Importantly, the difference in LPS compared to
untreated was far more significant than the difference in the genotype, regardless of wether the
sample was stimulated or not. Furthermore, when comparing the samples they would not clus-
ter with the genotype, instead only by stimulation, with some outliers. This indicates that even
though the mice had a reliable knock down of miRNA, this did not translate to an appreciable
difference in gene expression anywhere in the transcriptome.
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Figure 33:
Post-Alignment QAQC from Sequencing data. A. The overall quality of the reads was excel-
lent, indicating that the results were reliable. B. The PCA of all samples indicates that the differ-
ence in LPS stimulation is greater than the differences caused by the genotypes. C. Heatmap
with clustering using Euclidean distance, showing that the treatment of the samples clusters
much more reliably than the genotypes.
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7.5 Log2 Gene expression as determined by Nanostring
Table 10 (until page 91) has a list of the expression values of all genes analysed with the Nanos-
tring, and used in Figure 62. P-values, corrected for multiple comparisons with the Bonferroni
test (Extremely stringent) are included. Importantly, the BMDMs responded extremely well to
LPS. However, the differences between the two genotypes are negligible. Some genes, such
as Cyld, does show a significant change following stimulation in the miR-17-92∆, but not in the
littermate controls. There is however, no significant differences between the miR-17-92∆ and
littermate controls, indicating that there are subtle, yet potentially insignificant changes to gene
expression.
Mean expression log2 Bonferroni corrected p-values
Gene
Name WT LPS
miR-17-92∆
UT WT LPS
miR-17-92∆
LPS
KO vs WT
LPS
KO vs WT
UT
LPS vs UT
KO
LPS vs UT
WT
Acadm 10.48 10.56 10.26 10.40 1 1 1 0.39
Actb 17.79 17.76 17.79 17.77 1 1 1 1
Ager 3.69 3.66 3.55 3.49 1 1 1 1
Aim2 7.73 7.96 7.84 8.03 1 1 1 1
Ass1 10.66 10.78 10.99 11.14 1 1 0.27 1
Atat1 7.14 7.15 7.47 7.46 1 1 0.23 0.39
Atf3 11.27 11.32 11.32 11.23 1 1 1 1
Atp5J 11.04 11.05 11.05 11.11 1 1 1 1
Bst2 12.64 12.54 12.66 12.57 1 1 1 1
Casp1 10.22 10.28 10.75 10.71 1 1 3.12E-03 6.78E-04
Casp4 9.10 9.03 11.33 11.31 1 1 2.23E-12 6.81E-11
Casp8 9.15 9.08 9.06 8.96 1 1 1 1
Ccl17 3.36 3.67 7.05 6.65 1 1 2.08E-04 3.59E-05
Ccl2 11.91 12.27 14.83 14.55 1 1 0.33 0.09
Ccl20 3.36 3.59 5.76 5.46 1 1 7.98E-03 1.08E-03
Ccl22 5.31 5.50 8.84 8.42 1 1 2.82E-06 5.19E-07
Ccl3 11.23 11.77 15.32 15.22 1 1 3.79E-03 1.58E-03
Ccl4 9.54 10.13 14.83 14.68 1 1 8.80E-04 4.54E-04
Ccl5 8.33 8.60 12.92 12.46 1 1 1.71E-03 6.64E-04
Ccl7 10.37 10.69 12.80 12.54 1 1 1 0.69
Cd40 6.67 6.87 12.01 11.72 1 1 1.59E-07 2.21E-07
Ch25h 8.15 8.80 11.40 11.39 1 1 9.94E-03 1.90E-03
Chuk 9.62 9.64 9.84 9.83 1 1 0.03 0.02
Clec4e 10.18 10.57 13.81 14.05 1 1 2.60E-12 1.60E-11
Cltc 13.12 13.12 13.07 13.11 1 1 1 1
Csf3 2.96 3.39 6.94 6.42 1 1 9.63E-04 6.34E-05
Cxcl1 7.17 6.89 14.42 14.83 1 1 4.86E-23 1.77E-20
Cxcl10 8.10 8.08 13.86 13.70 1 1 7.48E-11 6.50E-10
Cxcl2 10.46 10.31 16.30 16.61 1 1 1.02E-25 2.46E-23
Cxcl3 6.02 6.17 12.36 12.59 1 1 8.09E-19 2.80E-17
Cxcl5 3.85 4.07 5.58 5.75 1 1 0.07 0.17
Table 10: Gene expression between miR-17-92∆and WT
BMDMs.
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Gene
Name WT LPS
miR-17-92∆
UT WT LPS
miR-17-92∆
LPS
KO vs WT
LPS
KO vs WT
UT
LPS vs UT
KO
LPS vs UT
WT
Cyld 8.92 8.99 9.24 9.31 1 1 0.03 0.12
Ddit3 9.66 9.65 9.20 9.37 1 1 1 1
Ddx41 3.10 3.16 3.57 3.49 1 1 1 1
Dectin1 11.13 11.17 11.01 11.14 1 1 1 1
Edn1 3.11 3.91 9.26 8.81 1 1 1.24E-03 1.92E-04
Eef1g 13.66 13.60 13.68 13.65 1 1 1 1
G6pdx 12.21 12.20 12.00 12.05 1 1 0.40 0.03
Gapdh 15.68 15.69 15.70 15.68 1 1 1 1
Gbp1 3.19 3.25 3.79 3.46 1 1 1 1
Gbp2 8.02 8.10 10.24 10.05 1 1 6.21E-05 4.66E-05
Gbp3 7.61 7.64 9.96 9.80 1 1 9.44E-06 1.64E-05
Gls 11.31 11.40 11.65 11.71 1 1 5.72E-03 8.41E-03
Got1 10.80 10.68 10.65 10.62 1 1 1 1
Gpt 6.33 6.27 6.17 6.30 1 1 1 1
Gsto1 10.84 10.84 10.94 10.95 1 1 0.06 1
Hk1 10.94 11.00 11.11 11.13 1 1 1 1
Hprt 10.01 10.07 10.09 10.11 1 1 1 1
Hsa90aa1 12.76 12.84 13.19 13.21 1 1 0.01 9.28E-03
Idh2 9.25 9.19 9.13 9.05 1 1 0.48 1
Ifi204 11.45 11.34 12.04 11.85 1 1 1 1
Ifit2 9.25 9.24 10.57 10.30 1 1 1 1
Ifit3 10.54 10.35 10.97 10.74 1 1 1 1
Ifitm3 13.82 13.93 14.24 14.22 1 1 1 0.29
Ifna1 3.61 3.59 3.48 3.62 1 1 1 1
Ifnb1 3.25 3.29 7.42 6.80 1 1 9.36E-04 3.39E-04
Ifng 3.82 4.00 4.69 4.35 1 1 1 0.29
Ikbkb 9.75 9.89 10.65 10.59 1 1 2.09E-03 2.60E-04
Ikbkg 9.50 9.58 9.39 9.49 1 1 1 1
Il10 5.89 5.91 10.12 9.63 1 1 1.75E-06 1.28E-06
Il11 3.61 3.65 4.21 4.07 1 1 1 1
Il12a 3.20 3.51 4.86 4.68 1 1 0.06 2.65E-03
Il12b 3.14 3.78 9.56 9.45 1 1 1.59E-06 1.23E-06
Il13 3.96 3.63 4.68 4.52 1 1 9.99E-03 0.37
Il15 8.28 8.34 10.31 9.98 1 1 7.29E-03 1.60E-03
IL16 6.41 6.66 5.74 6.08 1 1 3.60E-03 1.97E-03
Il18 7.68 7.68 8.05 7.97 1 1 1 1
IL18bp 7.20 7.23 7.38 7.39 1 1 1 1
Il18r1 3.87 3.77 4.73 4.70 1 1 0.22 1
Il1a 4.61 4.91 13.36 13.31 1 1 7.17E-11 4.13E-10
Il1b 7.21 7.11 15.23 15.43 1 1 2.72E-17 1.80E-15
Il1r1 5.63 5.39 5.95 5.96 1 1 0.10 1
Il1r2 5.93 6.12 6.32 6.44 1 1 1 1
Il1rap 7.83 7.84 8.08 8.08 1 1 0.03 0.10
Il1rl1 5.43 5.36 5.79 6.02 1 1 1 1
Il1rl2 5.43 5.51 5.85 5.95 1 1 0.80 1
Il1rn 10.69 10.86 13.06 12.78 1 1 0.01 2.58E-03
Il23a 3.64 4.21 9.37 8.81 1 1 9.45E-04 1.58E-04
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Gene
Name WT LPS
miR-17-92∆
UT WT LPS
miR-17-92∆
LPS
KO vs WT
LPS
KO vs WT
UT
LPS vs UT
KO
LPS vs UT
WT
Il27 4.29 4.52 8.47 8.09 1 1 7.89E-04 3.79E-04
Il33 4.08 4.27 5.00 4.72 1 1 1 0.03
Il6 3.70 4.31 9.92 9.73 1 1 9.29E-06 5.53E-06
Irak1 9.96 10.00 9.80 9.83 1 1 2.34E-03 0.02
Irak3 8.01 8.29 9.49 9.55 1 1 2.16E-03 1.09E-03
Irak4 9.65 9.66 9.31 9.42 1 1 0.09 3.67E-03
Irf3 9.15 9.19 9.23 9.30 1 1 1 1
Irf7 9.64 9.56 10.18 9.96 1 1 1 1
Irg1 8.42 8.82 14.35 14.60 1 1 1.04E-12 9.44E-12
Isg15 10.46 10.53 12.92 12.58 1 1 0.04 0.02
Itch 9.92 9.96 9.94 9.96 1 1 1 1
Ldha 14.19 14.14 14.18 14.15 1 1 1 1
Map3k7 9.46 9.45 9.55 9.62 1 1 7.87E-04 1
Mapk14 10.03 10.07 10.29 10.29 1 1 1 1
Mapk3 11.54 11.53 11.50 11.53 1 1 1 1
Mb21d1 7.52 7.72 8.45 8.37 1 1 1 0.17
Mdh2 11.92 11.90 11.89 11.90 1 1 1 1
Mefv 5.20 5.48 7.70 8.05 1 1 1.57E-11 4.63E-10
Mnda 11.94 11.91 13.54 13.36 1 1 0.01 0.01
Mx2 6.73 6.64 9.46 9.03 1 1 0.15 0.12
Myd88 9.58 9.71 10.60 10.57 1 1 4.31E-05 1.40E-05
Naip2 9.75 9.90 9.68 9.79 1 1 1 1
Naip5 7.37 7.46 7.08 7.23 1 1 1 1
Naip6 7.91 7.93 7.63 7.65 1 1 0.51 1
Nfe2L2 12.62 12.69 13.29 13.50 0.92 1 3.93E-11 5.18E-08
Nfkb1 10.73 10.82 12.65 12.57 1 1 1.90E-05 2.56E-05
Nfkbia 12.39 12.38 16.07 16.08 1 1 2.65E-29 8.68E-28
Nfkbib 8.95 9.09 11.19 11.08 1 1 9.97E-08 8.72E-08
Nlrc3 8.44 8.42 7.74 7.84 1 1 7.81E-05 2.75E-05
Nlrc4 7.24 7.29 7.88 7.92 1 1 1.95E-03 7.36E-03
Nlrc5 7.74 7.78 7.97 7.95 1 1 1 1
Nlrp10 4.70 4.64 4.40 4.50 1 1 1 1
Nlrp12 3.13 3.07 3.63 3.57 1 1 1 1
Nlrp1a 6.52 6.45 5.94 6.01 1 1 0.08 0.01
Nlrp1B 5.55 5.54 5.26 5.29 1 1 1 1
Nlrp3 10.67 10.94 13.44 13.51 1 1 3.28E-10 8.11E-10
Nlrp6 3.05 3.07 3.31 3.24 1 1 1 1
Nlrx1 6.72 6.88 5.98 6.19 1 1 4.61E-04 1.02E-03
Nod1 6.65 6.74 8.09 8.08 1 1 5.66E-06 1.24E-05
Nod2 6.60 6.74 10.09 10.25 1 1 4.15E-16 1.01E-14
Oas1b 5.69 5.67 6.33 6.06 1 1 1 1
Oas1g 9.47 9.55 10.16 10.05 1 1 0.91 0.13
Oas3 8.77 8.69 8.91 8.83 1 1 1 1
Oaz1 13.56 13.58 13.56 13.61 1 1 1 1
Otud7b 8.48 8.37 8.63 8.51 1 1 1 1
Peli1 9.87 10.03 12.40 12.26 1 1 3.45E-05 2.70E-05
Pgd 13.14 13.14 13.01 13.05 1 1 1 0.31
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Gene
Name WT LPS
miR-17-92∆
UT WT LPS
miR-17-92∆
LPS
KO vs WT
LPS
KO vs WT
UT
LPS vs UT
KO
LPS vs UT
WT
Phgdh 8.78 8.83 8.90 8.99 1 1 1 1
Pik3ap1 12.91 12.88 12.93 12.88 1 1 1 1
Pkm1 13.61 13.62 13.49 13.51 1 1 0.06 0.06
Pkm2 13.63 13.68 13.50 13.55 1 1 0.03 0.08
Ppia 15.49 15.56 15.51 15.60 1 1 1 1
Ppm1a 10.00 10.07 10.32 10.39 1 1 1.71E-05 8.59E-05
Prkaa1 10.52 10.53 10.48 10.53 1 1 1 1
Prps1 7.51 7.50 7.41 7.51 1 1 1 1
Ptgs2 7.27 7.30 12.46 12.55 1 1 7.11E-09 1.17E-07
Pycard 6.48 6.63 6.44 6.35 1 1 1 1
Rela 10.65 10.71 11.61 11.62 1 1 1.16E-08 5.48E-08
Relb 9.14 9.06 11.05 11.13 1 1 1.76E-16 3.31E-14
Ripk1 8.62 8.63 8.19 8.18 1 1 2.15E-04 2.16E-03
Rnf11 8.84 8.95 9.18 9.25 1 1 0.02 0.02
Rpl19 14.58 14.60 14.73 14.75 1 1 1.72E-06 7.94E-06
Rps6ka5 7.12 7.37 8.75 8.64 1 1 1.33E-03 1.30E-04
Rsad2 8.83 8.82 11.33 11.05 1 1 8.59E-03 7.94E-03
Saa3 6.12 6.57 12.10 12.00 1 1 1.61E-05 2.08E-05
Sdha 10.84 10.85 10.86 10.90 1 1 1 1
Sdhb 12.03 12.03 11.86 11.90 1 1 1 0.74
Serpinb2 5.64 5.74 8.96 8.89 1 1 3.67E-03 8.66E-03
Shpk 5.67 5.70 5.86 5.71 1 1 1 1
Sigirr 5.27 5.44 5.05 5.21 1 1 1 1
Slc27A1 12.53 12.48 12.15 12.16 1 1 0.01 8.35E-03
Slc6A3 3.67 3.64 4.34 4.43 1 1 5.62E-03 0.15
Smpdl3b 7.53 7.56 7.57 7.69 1 1 1 1
Socs1 6.81 7.29 10.35 10.04 1 1 7.25E-03 9.39E-04
Socs3 8.06 8.01 14.36 14.47 1 1 1.11E-25 6.02E-24
Stat1 11.55 11.39 11.65 11.46 1 1 1 1
Tank 10.20 10.43 11.83 11.85 1 1 2.97E-07 1.52E-07
Tax1bp1 10.81 10.82 11.36 11.34 1 1 2.18E-06 7.92E-06
Tbk1 9.80 9.90 10.38 10.39 1 1 1.83E-03 7.25E-04
Tbp 8.24 8.25 8.22 8.18 1 1 1 1
Tgfb1 9.55 9.56 9.48 9.64 1 1 1 1
Ticam1 8.32 8.47 8.84 8.88 1 1 1 1
Ticam2 8.37 8.27 8.66 8.67 1 1 1 1
Tirap 7.66 7.69 7.71 7.66 1 1 1 1
Tlr1 7.70 7.83 9.27 9.13 1 1 0.02 7.11E-03
Tlr2 10.97 10.95 13.16 13.39 1 1 1.98E-16 8.05E-14
Tlr3 7.66 7.63 7.78 7.64 1 1 1 1
Tlr4 10.98 10.90 10.28 10.30 1 1 2.08E-03 8.81E-04
Tlr5 5.87 5.76 5.12 5.18 1 1 0.30 0.06
Tlr6 7.18 7.16 7.52 7.56 1 1 0.20 1
Tlr7 9.63 9.65 9.84 9.88 1 1 1 1
Tlr8 10.70 10.66 10.16 10.17 1 1 7.90E-04 9.22E-04
Tlr9 9.10 8.84 8.40 8.28 1 1 0.09 0.02
Tmem173 9.27 9.22 9.14 9.13 1 1 1 1
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Gene
Name WT LPS
miR-17-92∆
UT WT LPS
miR-17-92∆
LPS
KO vs WT
LPS
KO vs WT
UT
LPS vs UT
KO
LPS vs UT
WT
Tnf 10.31 10.54 15.24 15.44 1 1 6.30E-18 1.26E-16
Tnfaip3 9.60 9.68 14.63 14.62 1 1 7.87E-20 1.16E-18
Tnfaip8l2 10.53 10.45 8.78 8.91 1 1 4.35E-04 3.32E-04
Tnfrsf1a 11.16 11.19 10.91 10.87 1 1 5.21E-03 0.32
Tnip1 9.16 9.41 11.99 12.06 1 1 1.80E-10 5.39E-10
Tnip2 8.42 8.51 9.03 8.94 1 1 0.04 1.29E-03
Tnip3 11.40 11.48 13.15 12.95 1 1 1.57E-04 5.16E-05
Traf1 8.04 8.13 11.29 11.19 1 1 1.85E-08 6.20E-08
Traf3 8.50 8.48 9.03 9.14 1 1 1.06E-04 0.01
Traf6 9.21 9.22 9.78 9.72 1 1 2.08E-07 1.39E-07
Trex1 9.93 10.03 12.11 11.95 1 1 1.92E-03 1.61E-03
Trim21 8.83 8.99 9.94 9.71 1 1 1 0.46
Trim30a 10.53 10.43 10.81 10.62 1 1 1 1
Tubb5 12.03 11.94 11.60 11.59 1 1 0.01 2.98E-03
Ube2n 6.93 7.05 7.14 7.24 1 1 1 1
Usp18 8.81 8.81 9.80 9.65 1 1 1 1
Usp21 8.16 8.23 8.06 8.07 1 1 1 1
Xbp1 11.74 11.74 11.61 11.68 1 1 1 1
Zfand6 10.65 10.70 10.86 10.88 1 1 0.03 0.03
Table 10: Gene expression between miR-17-92∆and WT
BMDMs.
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8 Abbreviations
Abbreviation Full phrase or term
AMO AntagomiR
ANOVA Analysis of Varience
BM Bone Marrow
BMDM Bone Marrow Derived Macrophage
BSA Bovine Serum Albumin
βME Beta-Mercaptoethanol (2-Mercaptoethanol)
cDNA Copy DNA
DC Dendritic cell
DESeq2 Differential gene expression analysis based on the negative binomial distribution
ELISA Enzyme-Linked immunosorbent assay
FCS Fetal Calf Serum
fl flox
iCLIP Individual nucleotide Cross-linking and Immunoprecipitation
IFN Interferon
Il Interleukin
ILC Innate Lymphoid cell
IP Intraperitoneal
L929 L929 cell conditioned medium
LPS Lipopolysaccharide
Mø Macrophage
M-CSF Macrophage Colony Stimulating Factor
miR-17-92∆ miR-17-92fl/fl - LysMCre cell/mouse
miRNA microRNA
mRNA Messenger RNA
NF-κB Nuclear Factor kappa B family
PAMP Pathogen Associated Molecular Pattern
PBMC Peripheral blood mononuclear cell
92
Abbreviation Full phrase or term
PCR Polymerase Chain Reaction
pre-miRNA precursor-miRNA
pri-miRNA Primary miRNA Transcript
PRR Pattern Recognition Receptor
qPCR Quantitative Real-Time PCR
RNA Ribonucleic Acid
RISC RNA-induced silencing complex
RT Reverse Transcription
TNFa Tumour necrosis factor alpha
TLR Toll-Like Receptor
UT Untreated
LysM-Cre Lysozyme 2 (Lyz2) driven Cre recombinase
WT Wild type: miR-17-92fl/fl mouse
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